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ABSTRACT
Mechanistic mathematical models of biological systems have been used to describe
biological phenomena, including human disease, in the hope that one day these models
may be used to better understand diseases, as well as to develop and optimize therapeutic
strategies. Evolutionary algorithms, such as genetic programming, may be used to
symbolically regress mathematical models describing chemical and biochemical species
for which kinetic data are available. However, current evolutionary algorithms are
restricted to the formulation of simple or approximate models due to the computational
cost of evolving mechanistic models for more complex systems.
It was hypothesized that chemical reaction kinetic theory could be used to
sufficiently reduce the model search space for an evolutionary algorithm such that it
would be possible to infer mechanistic mathematical models of complex biological
interactions. An evolutionary algorithm capable of formulating mass action kinetic
models of biological systems from time series data sets was developed for a system of nspecies using heuristics from chemical reaction kinetic theory and a gene expression
programming (GEP) based approach.

Jason Robert White – University of Connecticut, 2014

The resulting algorithm was then successfully validated on a general model of viral
dynamics that accounted for six pathways relating the change in viral template, viral
genome, and viral structural protein concentrations over time.
The algorithm was applied to generate cohort-specific models of HIV dynamics
from a clinical data set. HIV-1 infection models were defined as sets of two ordinary
differential equations describing the change in CD4+ T-cell and HIV-1 concentrations
over time. The evolved models were used to generate hypotheses regarding treatment
effectiveness and the potential for viral rebound in three cohorts of HIV-1 positive
individuals receiving different Highly Active Antiretroviral Therapy (HAART) regimens.
It was hypothesized by the algorithm that HAART was effective in stopping HIV-1
propagation in two of the three cohorts studied. In the other cohort, it was hypothesized
that HIV-1 continued to propagate and that there was the potential for viral rebound.
The result of this work was the development of an algorithm that can be used for
the generation of complex mechanistic biological models based upon kinetic data with
potential uses in fields ranging from biomedical to biotechnological.
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CHAPTER 1
INTRODUCTION
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1.1. Motivation
Mathematical models are used in nearly all industries to analyze data, make
predictions, and to propose improvements based upon those predictions. Most models
describing data sets are defined by optimizing parameters taken from pre-existing model
structures. Genetic programming allows one to carry out a symbolic regression to
simultaneously fit both the equation structure and the parameters to a data set requiring
only an input of the model variables and a set of available mathematical functions {+, -,
*, /, etc} (Holland 1975, Koza 1992). Thus far, model generation by genetic
programming has been restricted to the evolution of simple models due to challenges in
navigating the size of the search space for complex systems of equations.
Recently, work has been done on model generation from experimental data sets
without assuming any prior knowledge about system mechanism. Schmidt et al.’s Eureqa
formulize, a symbolic regression package that uses a genetic programming approach,
quickly fits models to input data (Schmidt and Lipson 2009). Although these models
provide a good fit to experimental data, they often do not provide mechanistic
information as to how species in a biological system interact. Chattopadhyay et al.
developed an algorithm for inferring stochastic reaction mechanism from experimental
data (Chattopadhyay et al. 2013). This algorithm was successful at generating correct
mechanistic models on the algorithm’s error-complexity Pareto front, but some
knowledge of the system was required in order to select the correct model from a set of
potential models. A study by Bazil et al. provided a method for the reverse engineering of
biological networks by generating systems of ordinary differential equations from
experimental data (Bazil et al. 2011). This algorithm was successful in identifying
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candidate pathways that were known to exist but also generated many false positive
pathways, as the algorithm was designed to minimize the number of false negative
pathways identified.
A common method used in these approaches is that of genetic programming.
Genetic programming is a type of evolutionary algorithm that generates programs or
models of varying size and structure while not assuming any pre-defined model structure.
The model is chosen by defining a set of functions (i.e. +, -, *, /), and a set of terminals
(i.e. variables, real numbers) as building blocks from which to construct equations (Koza
1992). Genetic programming works by generating a population of potential models of a
problem where each solution consists of the defined functions and terminals. The
potential models are ranked or scored based upon a defined fitness function. Models are
then selected, usually in proportion to their fitness score, to undergo recombination with
other models as well as for mutation. New models are incorporated with selected existing
models and the new population of models is carried on to the next iteration where the
algorithm repeats itself. A few examples where genetic programming has been used to
create models addressing many different problems include the evolution of natural laws
(Iba 2008, Schmidt and Lipson 2009), computer vulnerability testing (Kayacik et al.
2011), prediction of longitudinal dispersion coefficients in streams (Azamathulla and
Ghani 2011), protein binding sites (Bains et al. 2004), interpretation of microbial flow
cytometric data (Davey and Davey 2011), embedding and decoding of digital watermarks
(Usman et al. 2011), synthesis of polymorphic combinational circuits (Gajda and
Sekanina 2011), pipe break prediction modeling (Xu et al. 2011), estimation of daily pan
evaporation (Shiri and Kisi 2011), software engineering predictive modeling (Afzal and
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Torkar 2011), modular neural network programming (Tsai and Lin 2011), selfreproducing machines (Zykov et al. 2005), and steel beam load capacity prediction
models (Gandomi et al. 2011).
A desirable enhancement to the genetic programming approach would lead to an
extension of its use to the efficient generation of more complex mathematical models.
These models, such as multi-variate systems of ordinary differential equations, would
expand the use of this approach to model multi-variate data sets as are commonly found
in biological systems. Gene expression programming (GEP) has been proposed as an
enhancement to genetic programming (Ferreira 2006). In a GEP-type approach, solutions
are encoded as a linear sequence of functions and terminals during the selection,
recombination, and mutation operations. The encoded solutions are then mapped to
equations for simulation and scoring.
Mathematical modeling of viral systems such as HIV-1, hepatitis B, and others
has been of great interest in the hopes of developing treatment strategies based upon
those models (de Sousa and Cunha 2010, Guedj and Neumann 2010, Krishnan 2011,
Srivastava et al. 2002). Many models of various sizes and structures have been proposed
for these systems taking into account a wide range of biochemical species. Depending on
the species taken into account and their predicted relationships, the model behavior can
vary in response to perturbation. The most comprehensive approach to determine optimal
models describing such biochemical systems would be to assume no prior knowledge
about the systems and the way that the species interact. A symbolic regression approach
such as a GEP-based evolutionary algorithm could then be utilized to derive the
mechanistic model describing the species, taking into account all necessary species
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interactions including some that may not be inherently obvious. The resulting model
could then be used to make predictions about the system as well as to test and optimize
potential therapeutics.
Human immunodeficiency virus type 1 (HIV-1) is an important disease that has
received significant interest from the modeling community (Aviran et al. 2010,
Bonhoeffer et al. 1997(a,b), Burg et al. 2009, Herz et al. 1996, Nowak et al. 2000,
Perelson et al. 1996, Perelson 2002, Prosperi et al. 2009, Ribeiro and Bonhoeffer 2000,
von Kleist et al. 2010, Wu and Zhang 2010, Zeng and Yang 2010). In recent years, HIV1 treatments have significantly reduced AIDS-related mortalities and have enhanced
long-term disease control (Dybul et al. 2001, Fagard et al. 2003, Powderly 2002, Ruiz et
al. 2001). These benefits have been realized in large part via use of highly active
antiretroviral therapy (HAART) in clinical practice. The HAART strategy consists of
treating the disease with a combination of antiretroviral drugs. Despite advances in
efficacy over prior generation treatments, HAART is associated with risk of serious side
effects that include cardiovascular disease (Domingos et al. 2009), nephrotoxic effects
(Izzedine et al. 2009), and oral toxicities (Nittayananta et al. 2010). Up to 16% of
patients require modification or discontinuation of their HAART regimen due to drugrelated toxicities (El-Sadr et al. 2006).
	
  
1.2 Specific Aims
I hypothesize that using reaction kinetic theory to constrain model space, it is
possible to infer mechanistic mathematical models of complex biological interactions by
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using an evolutionary algorithm to carry out symbolic regression. To test this hypothesis,
the following specific aims were pursued:
1. The development of a GEP-based evolutionary algorithm that optimized reaction
kinetic models of biological systems from time series data sets.
2. The generation of cohort-specific reaction kinetic models of Human
Immunodeficiency Virus (HIV) infection from a clinical data set.
To address these specific aims, the current symbolic regression methodology termed
genetic programming was enhanced using a GEP-based approach to evolve more
complex mechanistic reaction kinetic models describing multi-variate data sets. Also,
experience in modeling HIV infection and simulating treatment outcomes was used to
identify a clinical data set on which the GEP-based evolutionary algorithm was applied.
Completion of aims 1 and 2 resulted in an algorithm that could efficiently
determine a model structure and parameters to a moderately sized time series data set.
The algorithm required no prior knowledge of the relationship among measured
variables. The enhancements to the genetic programming approach also allowed for the
generation of models containing many variables. Interactions between large numbers of
variables are commonly found in biological systems. The algorithm therefore will be
beneficial in generation models of complex biological systems. Models describing
biological systems have the potential to guide the discovery of drug targets and
therapeutic strategies. This technology also has the potential to be useful in personalized
medicine applications. The tailoring of mathematical models to an individual’s disease
state based upon their unique biochemical kinetic markers would allow clinicians to make
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predictions about an individual’s disease state and to optimize treatment to the individual
patient.

1.3. Outline
In Chapter 2, it is demonstrated how mathematical modeling can be used to
simulate the progression of a disease. A mass action kinetic model was used to describe
nine biochemical species involved in the pathogenesis of oral cavity mucositis. The
parameters of the model were optimized to a heterogeneous data set based on the shared
pathway assumption.
In Chapter 3, the topic of evolutionary algorithms is introduced as the
performance of the genetic algorithm operation termed “selection” was evaluated. It was
found that a novel selection strategy, termed elite-variant selection, greatly improved the
performance of the genetic algorithm in a variety of application tests. One of these tests
included the optimization of a theoretical Highly Active Antiretroviral Therapy
(HAART) regimen to an in silico HIV-positive subject.
In Chapter 4, a systems biology analysis is applied to clinical HAART regimens,
termed Standard Treatment Interruption (STI) regimens, which were utilized to
potentially treat a subject’s HIV while also administering less HAART. Clinically, these
STI regimens were found to be unsuccessful compared to standard HAART and the
systems biology approach was able to predict this without exposing subjects to a clinical
trial. Further, using a systems biology approach it was shown that an optimal HAART
regimen could be found that would control a subject’s HIV while also minimizing
HAART dose and thereby reducing the risk of serious side effects.
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In Chapter 5, an evolutionary algorithm is described that evolves reaction kinetic
models of biochemical systems from time series data sets. This was accomplished by
enhancing the genetic programming methodology by using a GEP-based approach where
reaction kinetic knowledge is leveraged and potential models are considered and
optimized. This algorithm, significantly, assumes no prior knowledge of how
biochemical species that play key roles in disease pathogenesis interact and it allows for
the discovery of pathways that may exist between these species.
In Chapter 6, the GEP-based evolutionary algorithm was used to evolve cohortspecific reaction kinetic models describing clinical data taken from HIV-positive
subjects. These models described important pathways that were active in the different
cohorts and were able to give insight as to the effectiveness of HAART regimens in
controlling the propagation of HIV in these cohorts.
This work is concluded in Chapter 7 and Chapter 9 contains the Appendices. In
Appendix 1, Common Lisp code of the elite-variant selection strategy is provided to
complement Chapter 3. In Appendix 2, Common Lisp code that generates in silico HIVpositive populations and simulates HAART on these populations is provided to
complement Chapter 4. In Appendix 3, the GEP-based evolutionary algorithm and
associated packages are provided as Mathematica code. This code complements Chapter
5 and was applied to HIV-positive cohort data in Chapter 6.
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CHAPTER 2
MODELING OF ORAL CAVITY MUCOSITIS
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2.1 Introduction
One example of the utility of using mathematical models to describe biological
phenomena is the optimization and analysis of a network describing oral cavity
mucositis. The work presented in this Chapter is my contribution of the work published
in the proceedings of the American Society of Clinical Oncology (Peterson et al. 2008,
Srivastava and White et al. 2011). Oral cavity mucositis is a condition observed in cancer
patients receiving radiation therapy or chemotherapy. It is characterized by inflammation
followed by sepsis and bacterial infection in the oral cavity (Knox et al. 2000, Niscola et
al. 2007, Peterson 1999, Sonis 2004). The result of this condition is significant pain,
interruption of therapy, increased costs due to hospitalization, and in some cases death
(Lalla et al. 2008, Peterson et al. 2007). Figure 2.1 depicts changes in the oral mucosa
during as a result of this disease.

Figure 2.1. Oral Mucosal Biopsies In Autologous Stem Cell Transplant Patients (Peterson et
al. 2008). The histopathologic specimens shown here were directly obtained via oral mucosal
biopsy specimens in autologous stem cell transplant patients prior, during and following
resolution of acute mucositis caused by a high-dose conditioning regimen. The specimens
illustrate tissue-based changes that are relevant to oral mucositis data.
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Recent basic research advances have strategically contributed to (i) defining
pathobiology of alimentary tract mucosal injury secondary to cancer therapy and (ii)
linking molecular mechanisms with clinically important outcomes. Use of analytic
technologies to integrate biological, clinical and computational domains represents an
important new direction in the field, such that gaps in existing knowledge can be
translated into novel hypotheses as well as prediction of experimental outcomes. The
prototype presented in this study provides the basis for development of a detailed
mathematical model for quantifying relevant components of the mucositis pathway.
Oral and gastrointestinal mucositis can be a major toxicity secondary to high-dose
cancer therapies, including chemotherapy and radiation administered as single agent or
combined treatment (Peterson and Sonis 2001). Potential clinical and mechanistic
relationships between selected targeted cancer therapies and mucosal injury have recently
been reported as well (Keefe and Gibson 2007). Nearly all patients receiving radiation
therapy for head and neck cancer develop clinically significant oral mucositis, with 16%
requiring hospitalization because of its severity (Lalla et al. 2008). Severe oral mucositis
results in unplanned radiation therapy treatment interruptions in 11% of patients. Patients
undergoing multi-cycle chemotherapy for solid tumors are also at risk. For example, 303
of 599 patients (51%) receiving chemotherapy for solid tumors or lymphoma developed
at least World Health Organization Grade 3 oral and/or gastrointestinal mucositis.
Reduction in subsequent dose of chemotherapy was twice as common after cycles with
mucositis than after cycles without mucositis, thus creating the potential for less than
optimal tumor response.
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Current work is fostering development of novel, molecularly targeted
interventions to reduce severity and duration of oral mucositis in selected cancer patient
cohorts (Peterson et al. 2007). Important principles of the current pathobiologic model of
mucositis include the role of pro-inflammatory cytokines (Sonis 2007), tissue-based
genetic risk and resistance mechanisms (Belinsky et al. 2007, Boerma et al. 2007, Duan
et al. 2007) and symptom clusters (Aprile et al. 2008, Campagnaro et al. 2008).
However, key gaps in knowledge remain across the molecular, tissue and clinical
continuum relative to strategically advancing this multidimensional modeling. In this
study, it was shown that Virtual Cell (http://vcell.org) (Schaff et al. 1997, Slepchenko et
al. 2003) represents a unique technology to address these complex research issues. Effort
was directed to development of a new computational strategy to bridge “top down”,
clinically-based events with complex, “bottom up” molecular pathways. It was
demonstrated that using computational modeling fosters integration of data from recent
studies (Jain et al. 2006, Knorr and Srivastava 2005, Moraru and Loew 2003, Schaff et
al. 1997, Slepchenko et al. 2003) that have characterized pathways associated with upregulation of pro-inflammatory molecules including NF-κB, COX-2 and IL-6. The goal
of this research was to provide new molecular insights into both causation of alimentary
tract mucosal injury in cancer patients as well as the relationship of associated pathways
to clinical consequence with the hope of forming novel hypotheses on how to downregulate this condition.
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2.2 Methods
Integration of available data into a coherent model is an important approach to
precisely defining the collective molecular complexities of mucositis. Determination of
the physiological characteristics that the model is able to capture is designed to elucidate
specific components and mechanisms. The current paradigm capitalizes on prior studies
in order to generate this new line of research (Jain et al. 2006, Knorr and Srivastava
2005, Moraru and Loew 2003, Schaff et al. 1997, Slepchenko et al. 2003). The current
view of mucositis pathogenesis includes the theory of multiple shared pathways across
the continuum of alimentary tract mucosa (Sonis 2007). A “systems biology” approach,
in which data collected from these shared pathways are leveraged and integrated into a
comprehensive computational model of mucositis, can potentially define commonalities
and differences among causation of the collective mucosal injury. Using these shared
pathways as a foundation, it is possible to apply the theory of reaction kinetics to develop
a mathematical model of the interactions among what are believed to be key components
involved in mucositis. The current model that I assembled accounts for interaction
dynamics among COX-1, COX-2, TNF-α, PGE-2, IL-1β, IL-6, PGI-2, TXA-2 and NFκB, and includes the effect of biological feedback loops among all the species (Peterson
et al. 2008). The model is described by Equations 2.1-2.9 and is depicted as a network
structure in Figure 2.2.
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𝑑 𝑁𝐹 − 𝜅𝐵
= 𝑘! + 𝑘! 𝑇𝑁𝐹 − 𝛼 + 𝑘! 𝐼𝐿 − 1𝛽 + 𝑘! 𝑃𝐺𝐸 − 2
𝑑𝑡

(2.1)

−𝑘! [𝑁𝐹 − 𝜅𝐵]

	
  

𝑑[𝑇𝑁𝐹 − 𝛼]
= 𝑘! + 𝑘! 𝑁𝐹 − 𝜅𝐵 − 𝑘! [𝑇𝑁𝐹 − 𝛼]
𝑑𝑡

(2.2)

𝑑[𝐼𝐿 − 1𝛽]
= 𝑘! + 𝑘!" 𝑁𝐹 − 𝜅𝐵 − 𝑘! [𝐼𝐿 − 1𝛽]
𝑑𝑡

(2.3)

𝑑[𝐶𝑂𝑋 − 2]
= 𝑘!" − 𝑘!" [𝐶𝑂𝑋 − 2]
𝑑𝑡

(2.4)

𝑑[𝐶𝑂𝑋 − 1]
= 𝑘!" − 𝑘!" [𝐶𝑂𝑋 − 1]
𝑑𝑡

(2.5)

𝑑[𝑃𝐺𝐸 − 2]
= 𝑘!" 𝐶𝑂𝑋 − 2 + 𝑘!" 𝐶𝑂𝑋 − 1 − 𝑘!" [𝑃𝐺𝐸 − 2]
𝑑𝑡

(2.6)

𝑑[𝑃𝐺𝐼 − 2]
= 𝑘!" 𝐶𝑂𝑋 − 2 + 𝑘!" 𝐶𝑂𝑋 − 1 − 𝑘!" [𝑃𝐺𝐼 − 2]
𝑑𝑡

(2.7)

𝑑[𝑇𝑋𝐴 − 2]
= 𝑘!! 𝐶𝑂𝑋 − 2 + 𝑘!" 𝐶𝑂𝑋 − 1 − 𝑘!" [𝑇𝑋𝐴 − 2]
𝑑𝑡

(2.8)

𝑑[𝐼𝐿 − 6]
= 𝑘!" + 𝑘!" 𝑁𝐹 − 𝜅𝐵 − 𝑘!" [𝐼𝐿 − 6]
𝑑𝑡

(2.9)
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Figure 2.2. Oral Mucositis Network Schematic (Peterson et al. 2008). Oral mucositis is
initiated by chemotherapy or radiation therapy. The transcription factor NF-κB is activated
directly by these therapies or through the production of reactive oxidative species. NF-κB upregulates many genes including the cytokines IL-6, IL-1β, and TNF-α. The enzymes COX-1 and
COX-2 are also up-regulated which in turn catalyze the production of the PGE-2, PGI-2, and
TXA-2 cytokines. PGE-2, IL-1β, and TNF-α can feedback to activate additional NF-κB. The “*”
represents constitutive processes and red bars denote degradation reactions.

To conduct the computational simulation, it was necessary to associate a
parameter with each reaction. Estimation of parameter values was conducted using the
Virtual Cell software platform (Schaff et al. 1997, Slepchenko et al. 2003), based on a
combination of data in the literature and primary experimental data. Ideally, the collective
kinetic data should be based on a single cohort of human studies of oral mucositis.
However, the relatively limited scope of published data often dictates that heterogeneous
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data sources be used. These sources may include data from different human studies, or
from studies using animal models such as murine or rat. A literature survey, conducted to
delineate necessary data to estimate the parameters, determined that the quantity of
kinetic data for many of the oral mucositis reactions was sparse to non-existent, even
when evaluating heterogeneous data sources. For example, no data on PGE-2 kinetics for
oral mucositis was found in any animal model or human studies. Based on the shared
pathway assumption, PGE-2 kinetic data from murine inflammatory bowel disease (IBD)
modeling was ultimately utilized (Melgar et al. 2006).

2.3 Results
Reaction parameters for the oral mucositis model were estimated using Virtual
Cell and are reported in Table 2.1. Once parameters for the model based on data from
oral mucositis and IBD were estimated, it was possible to carry out simulations of the
mucositis process. The timeframe examined was divided into two components. The first
15 days post-chemotherapy involved the “injury and wounding phase” of tissue toxicity.
The remaining 85 days were identified as the “healing phase.” It was experimentally
observed that seven of the nine species reached a plateau in species concentration over
the observed 100-day timeframe (Peterson et al. 2008). The only species not to reach a
plateau during the healing phase were TXA-2 and PGI-2. The model was capable of
predicting the difference between the initial and plateau values of the seven remaining
species within experimental error.
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Table 2.1. Oral Mucositis Model Parameters
k1

12.49 uM NF-κB/day

k10

k19

51.63 pg/ml/(day*ng mRNA)

k11

100.97 mRNA/GAPDH/(day*uM
NF-κB)
90.67 1/day

k2

10.10 uM NF-κB/(day*mRNA)

k20

448.04 pg/ml/(day*ng mRNA)

k3

12.21 uM NF-κB/(day*mRNA)

k12

119.97 ng RNA/(day*uM NF-κB)

k21

0.02 1/day

k13

2.71 1/day

k22

55.59 pg/ml/(day*ng mRNA)

k5

2.71*10 uM NF-κB/(day*pg/100
mg tissue)
53.17 1/day

k14

1738.18 ng mRNA/day

k23

3675.93 pg/ml/(day*ng mRNA)

k6

463.67 mRNA/GAPDH/day

k15

6.12*10-18 1/day

k24

0.03 1/day

k7

k16

36.36 mRNA/GAPDH/day

k26

k9

105.16 mRNA/GAPDH/day

k18

8.88*10-19 pg/100 mg
tissue/(day*ng mRNA)
40.54 pg/100 mg tissue/(day*ng
mRNA)
0.04 1/day

k25

k8

5.28*10-19
mRNA/GAPDH/(day*uM NF- κB)
1269.85 1/day

56.80 mRNA/GAPDH/(day*uM
NF- κB)
351.37 1/day

k4

-6

k17

k27

Results for five of the seven species are shown in Figure 2.3, with the remaining
two species not shown due to the differences in scale. In studying the dynamics during
the injury and wounding phase of the molecular species involved in mucositis, the model
was able to reproduce the dynamics of TXA-2 and PGI- 2, which were the only species
not to reach a plateau (Peterson et al. 2008). The model was unable to reproduce the
dynamics observed in this phase for the other species. The inability to reproduce these
dynamics may be due to a number of reasons: (i) the interactions among the components
may be incomplete or erroneous; (ii) the differences among kinetics of the shared
pathways may be sufficiently significant to make the shared pathway assumption a poor
one in this case; or (iii) variation among different data sources (human, mouse, and rat)
may be result in substantial, detrimental impact estimation of reaction parameters. This
work therefore highlights the importance of conducting appropriately designed
experiments from a single cohort of test subjects. In doing so, it will be possible to
remove inaccuracies associated with the last two confounders cited above, namely, the
shared pathway assumption and the use of heterogeneous datasets.
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Figure 2.3. Results of Oral Mucositis Model Simulations (Peterson et al. 2008). The
difference between initial species level and final plateau levels are illustrated for the Virtual Cell
simulation versus experimental data and data from the literature (Lipniacki et al. 2004, Sun et al.
2001). The units for NF-κB are µm, for COX-2 are ng of mRNA, and for IL-1β, IL-6 and TNF-α
are mRNA levels normalized for GAPDH. Note that the NF-κB data derive from an independent
simulation (Lipniacki et al. 2004); they thus do not have an associated experimental error. This
analytic strategy with NF-κB illustrates the ability of the modeling to integrate data from diverse
sources.

2.4 Discussion
Mucositis can be a significant dose-limiting complication of cancer therapy.
Higher-dose cancer treatment regimens might become feasible if the toxicity could be
prevented or substantially reduced in severity. More aggressive cancer therapies could in
turn produce higher cancer cure rates and/or more durable remissions. There are a
number of potential benefits to utilizing a systems biology approach to enhance the
modeling of mucositis. The simulations completed to date have been important in two
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respects. First, they have highlighted key gaps in the literature that need to be addressed.
Second, a number of key experiments have been suggested, along with how those
experiments should be designed. An example of implementing these two outcomes is
directed to detailed analysis of interactions among species during the injury and
wounding phase, particularly at the very early stages. To this end, an important specific
experiment would involve study of kinetic data for PGE-2 dynamics. Furthermore, a
homogeneous dataset needs to be collected from a single cohort for the molecular species
in question. Ideally, a human cohort should be utilized. However, studies from animal
models could also prove to be highly beneficial if integrated into a single, comprehensive
experiment. As the model matures, it will permit study of additional key avenues of
research including studying the mechanisms by which selected oral mucosal sites (e.g.,
hard palate) are relatively resistant to high-dose cancer therapy, while other sites are
highly susceptible to injury (e.g., buccal mucosa, soft palate) and selected non-oral
mucosal sites (e.g., conjunctival mucosa) are rarely clinically affected by high-dose
chemotherapy, while other sites (e.g., selected oral mucosal sites) are highly susceptible.
Future applications could also include the study of pharmacologic interventions
that enhance tumor susceptibility to cancer therapy as well as reducing mucosal injury.
This technology represents an innovative strategy to accelerate future laboratory and
clinical investigations directed to network pathways and cancer treatment research. The
model-based analysis has potential for utilization for personalized medicine. By
determining the specific parameters of an individual, the technology could evaluate
customized mucositis management strategies for that patient, with resultant reduction in
cancer treatment toxicity.
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CHAPTER 3
DEVELOPMENT OF AN ELITE-VARIANT SELECTION STRATEGY FOR
GENETIC ALGORITHM OPTIMIZATION
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3.1 Introduction
The work presented in this Chapter is my contribution towards an oral
presentation given by me at the Biomedical Engineering Societies Annual Meeting in
2011 (White and Srivastava 2011). Significantly, I demonstrate how an improvement to
the genetic algorithm selection operation results in rapid convergence of the algorithm in
many cases. Because genetic algorithm approaches are often computationally intensive,
this approach has the benefit of greatly reducing the time needed to converge upon a
desired solution.
Genetic algorithms are a subset of evolutionary algorithms used to optimize
solutions to complex problems by means of evolving a solution most fit to solve a given
problem from a pool of possible solutions (Arnold and Beyer 2006, Bäck 1996, Fang et
al. 2010, Goldberg 1989, Holland 1975, Iba 2008, Schwefel 1993, Tang and Wu 2009).
During the course of this evolution, possible solutions, referred to as chromosomes, are
selected to undergo recombination and mutation so that better solutions may be
discovered while also maintaining diversity in the population of solutions. This diversity
in the population of solutions allows for a broad search of the solution space so that the
population will not prematurely converge to a local optimum. The cycle of selection,
recombination, and mutation either repeats itself for a set number of iterations, also
known as generations, or until a specified termination criterion has been reached.
Although extensive research on different approaches for carrying out selection,
recombination, and mutation in evolutionary algorithms has been carried out (De Jong
and William 1991, Deb et al. 2002, Eremeev 2008, Gallagher and Frean 2005, Gero and
Kazakov 2001, Jansen et al. 2005, Nomura and Shimohara 2001, Rowe et al. 2004,
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Whitley 1989), this work will focus primarily on selection.
Common examples of selection methods include Tournament selection,
Proportional selection, Linear Ranking selection, and Elite selection. The Tournament
selection approach involves selecting the chromosome which is the best fit of a randomly
populated sub-population of specified size to take part in recombination and mutation
with another chromosome selected in the same manner (Blickle and Lothar 1995). By
doing this, Tournament selection balances convergence of the population to an optimum
with maintaining population diversity so that the population does not become uniform at
a local optimum thereby giving it a chance to arrive at the global optimum. Likewise,
Proportional selection maintains this balance by assigning a weight to each chromosome
proportional to its fitness score (Schwefel 1993). In this way, selecting a chromosome to
take part in recombination and mutation can be related to spinning a roulette wheel where
the slot size is proportional to the fitness of the chromosome with the most fit having the
largest slot and the least fit having the smallest slot. Like Tournament selection, the fittest
chromosome in a population is not guaranteed to enter into recombination or be carried to
the next generation, but has the greatest likelihood of doing so.
Linear Ranking selection attempts to overcome the bias that may enter
Tournament or Proportional selection when a “super chromosome”, or a chromosome
that is significantly fitter than other chromosomes, enters the population by weighting
chromosomes in the population relative to fitness rank rather than fitness score (Baker
1985). A linear relationship between rank and likelihood of being selected is then
established so that the top ranked chromosome will be the most likely to be selected, and
the last ranked chromosome will be the least likely to be selected. Addressing this bias in
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Proportional and Tournament selection may avoid a situation where a “super
chromosome” is continuously selected for recombination, leading to a homogenized
population that plateaus at a local optimum resulting in an undesirable solution.
Finally, Elite selection is a method that balances convergence with population
diversity by copying an “elite” fraction of chromosomes untouched to the next
generation, thereby keeping better scoring genetic material for use in the next generation
(Costa and Oliveira 2003). The remainder of the new generation is populated by
chromosomes that are randomly selected and are either simply copied or undergo
recombination and/or mutation based on some pre-determined probability. This selection
method has the advantage of being able to progress towards the optimum by means of
keeping the best genetic material in the population. Elite selection also maintains
population diversity by selecting random chromosomes for recombination and mutation
without regard to fitness score or rank.
The goal of this work was to achieve an improvement in the balance between
convergence and population diversity in genetic algorithm selection, which will
ultimately allow desirable solutions to be reached faster. It is hypothesized that the
selection process in genetic algorithms can be configured in such a way that convergence
to a global optimum or termination criterion will occur in a timely fashion for a large
scope of problems, while also broadly probing the search space in order that the
population of solutions does not plateau at a local optimum. Such a selection method
would offer a clear improvement over currently existing selection methods. In an effort to
address these goals, an Elite Variant (EV) selection strategy is presented. The EV
selection strategy has been designed to take the desirable aspects of Elite selection one
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step further to a selection strategy that converges more rapidly than the Elite selection
method while maintaining the ability to preserve a diverse population and a broad search
of the solution space.
	
  
3.2 Methods
3.2.1 Development of Elite Variant Selection Genetic Algorithm
Genetic algorithms follow a common methodology of utilizing selection,
recombination, and mutation operators to evolve a population of possible solutions
towards the optimal solution. The selection operator determines which possible solutions
or chromosomes are selected to undergo recombination. The recombination operator then
determines whether the selected chromosomes will pass to the next generation unaltered
or recombined. If the chromosomes are to be recombined, one or more chromosome
positions are randomly selected at which genetic material from the selected chromosomes
will be exchanged. Finally, each position or allele in each selected chromosome is given a
small chance to be mutated to a different value.
Implementation of a genetic algorithm using Elite Variant (EV) selection,
summarized in Figure 3.1, may be carried out as follows. An initial pool of a specified
size is populated by possible solutions or chromosomes. The user specifies the nature of
these possible solutions. The chromosomes in the population are then scored in relation to
a defined scoring metric. Depending on the nature of the problem, one may wish to
maximize or minimize the scores of the chromosomes to a desired global optimum or
user-specified termination criterion. For the first iteration or generation, the algorithm
behaves as the Elite selection strategy algorithm does, and a fixed percentage of the best
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scoring chromosomes are copied to the next-generation population. For this study the top
20% of the best scoring chromosomes was chosen to be copied to the next generation
when using the Elite selection strategy, although another appropriate fraction could be
chosen.
The final 80% of the next generation are then composed of pairs of chromosomes,
which are selected randomly and given a 70% probability to breed or recombine with
each other. After this recombination step, each part of both chromosomes is given an
opportunity to mutate. The chance of mutation is set at 5% in order to ensure a diverse
population. Random pairs of chromosomes are selected for the recombination and
mutation steps until the size of the next-generation population equals that of the initial
population. My code written in Common Lisp for the EV selection strategy can be found
in Appendix 1.
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Figure 3.1. Genetic Algorithm Using Elite
Variant Selection (White and Srivastava 2011).
A genetic algorithm using Elite Variant selection
will require input as to the desired population
size,

chromosome

length,

and

termination

criterion. This diagram assumes that the objective
function is to minimize the chromosome score.
The first generation of the EV selection algorithm
will always use Elite selection. Starting with the
second generation, the algorithm will check every
generation to see if Elite Variant or Elite selection
should be used. The output of the algorithm will
be a scored population of chromosomes, where
the best scoring chromosome can be considered
the optimized solution given the scoring metric
and termination criterion. The use of Elite Variant
selection will facilitate “leaps” in the evolution of
the population of chromosomes while the use of
Elite selection will give the population a means of
escaping a local optimum.
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The algorithm then iterates and returns to the scoring step. The next-generation
population becomes the current working population and is scored and sorted. At this
point, EV selection is called. First, the score of the top-scoring chromosome in the
current population is compared to the top-scoring chromosome of the previous
generation. If the scores are the same, it is assumed that the top-scoring chromosome is
currently at some local optimum. In this case, the algorithm continues to populate the
next-generation population according to the Elite selection strategy, as in the first
generation. If the top-scoring chromosome of the current generation is better (higher or
lower depending on if the problem is a maximization or minimization problem), then the
algorithm proceeds according to EV selection in an attempt to facilitate convergence
along the current path. First, the top-scoring chromosome is copied to the next
generation. In the case of an even population size, the first two top-scoring chromosomes
are copied to the next generation. The rest of the next-generation population is made up
of chromosome pairs containing one random chromosome and the best-scoring
chromosome. These chromosome pairs are then recombined. Two random chromosome
positions are selected at which genetic material is exchanged. Each part of the
recombined chromosomes is also given a 5% chance to mutate.
The algorithm once again iterates to the next generation and continues to iterate
until a specified amount of generations have been completed or a termination criterion
has been reached. The critical decision point in each generation is whether or not the
best-scoring chromosome in the working generation is better scoring than the bestscoring chromosome of the previous generation. If the scores are equal, then the nextgeneration population is determined according to the Elite selection strategy, while if the
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score has improved, the next-generation population is determined according to the EV
selection strategy.
The purpose of the EV selection method is to facilitate “leaps” in the evolution of
the population while at the same time maintaining its diversity and ability to search a
broad range of the solution space as to not plateau at some local optimum. This is
accomplished first by preserving genetic material that yields a good score in comparison
to other genetic material and by also breeding that genetic material with other randomly
selected chromosomes to possibly create even better chromosomes. Since the bestscoring chromosome is forced to breed with other randomly selected chromosomes in EV
selection generations, the algorithm is pushed to continually improve at a rapid rate. At
the same time, the algorithm can maintain its diversity by reverting back to the Elite
selection strategy when an improvement is not discovered. The mutation rate is also set to
5%, a high rate when compared to most genetic algorithm applications, in an effort to
maintain adequate diversity.

3.2.2 Application of Test Cases to Elite-Variant Selection Genetic Algorithm
In an effort to compare Elite Variant selection to other commonly used selection
methods, genetic algorithms using EV, Elite, Tournament, Proportional, and Linear
Ranking selection were applied to multiple test problems taken from the literature.
Five test functions were used to evaluate the ability of genetic algorithms using
each selection strategy to evolve to a global optimum (Oltean 2005). The functions used
are listed in Table 3.1. Each algorithm in all five tests had a population size of 100
chromosomes and a chromosome length of 100 integers. The integers comprising the
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chromosomes were initialized randomly to values between -100 and 100 for Function
Test 1, between -10 and 10 for Function Test 2, between -30 and 30 for Function Test 3,
between -5 and 5 for Function Test 4, and between -500 and 500 for Function Test 5. The
optimal solution for all five test functions was a chromosome made up entirely of 0’s
which would yield a score of 0. The goal therefore was to minimize the chromosome
score. Each algorithm was programmed to terminate after 25,000 generations. For each
function test, 50 trials were conducted per selection strategy.
	
  
Table 3.1: Genetic Algorithm Function Tests (Oltean 2005)	
  
n

F1 = ∑ (x i2 ) 	
  

Function Test 1	
  

i=1
n

n

i=1

i=1

F2 = ∑ x i + ∏ x i 	
  

Function Test 2	
  
n−1

Function Test 3	
  

F3 = ∑ (100 * (x i+1 − x i2 ) 2 + (1− x i ) 2 ) 	
  
i=1
n

Function Test 4	
  

F4 = 10 * n + ∑ (x i2 −10 * cos(2 * π * x i )) 	
  
i=1

Function Test 5	
  

F5 =

n
1 n 2
x
(x i ) − ∏ (cos( i )) + 1	
  
∑
4000 i=1
i
i=1

	
  
Next, a satisfiability problem (De Jong and William 1991, Lardeux et al. 2006)
was tested on each selection strategy. In this case, the desired solution was a binary string
of 0’s and 1’s specified by the user. One point was added to the score of a chromosome
for each position that did not match the desired solution. For example, if position 29 in
chromosome 39 contained a “1”, but position 29 of the solution contained a “0”, one
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point was added to the score of chromosome 39. The goal was to minimize the
chromosome score; a score of zero would signal that the solution had been found. In this
study, the solution was randomly generated prior to every trial and each position in the
initial population of chromosomes was initialized between 5 and 10 so that each trial was
initialized at a sufficiently unsatisfactory solution. The population was again set to 100
chromosomes and the chromosome size was also set to 100 positions or alleles. It was
again observed how quickly and how close a genetic algorithm with a specified selection
strategy could evolve towards the optimal solution. The termination criterion was set to
25,000 generations. For each selection strategy, 50 trials were again carried out.
Finally, a complex problem involving the use of genetic algorithms to evolve
Highly Active Antiretroviral Therapy (HAART) regimens for Human Immunodeficiency
Virus (HIV) subjects was explored using EV as well as the other selection strategies
under investigation. The problem constituted determining an optimum 200-day HAART
dosage schedule for a theoretical subject described by a mathematical model. The model
is given by Equations 3.1-3.5 and is schematically depicted in Figure 3.2 as a
biomolecular reaction kinetic network (Wu and Zhang 2010).

𝑑[𝑇! ]
= 𝑘! − 𝑘! 𝑇! − 𝑘! 1 − 𝑅𝑇 𝑉! 𝑇! − 𝑘!" [𝑉! ][𝑇! ]
𝑑𝑡

	
  

(3.1)

𝑑[𝑇! ]
= 𝑘! 1 − 𝑅𝑇 𝑉! 𝑇! − 𝑘! [𝑇! ]
𝑑𝑡

(3.2)

𝑑[𝑇! ]
= 𝑘!" 𝑉! 𝑇! − 𝑘! [𝑇! ]
𝑑𝑡

(3.3)

𝑑[𝑉! ]
= 𝑘! 1 − 𝑘!! 1 − 𝑃𝐼 𝑇! − 𝑘! [𝑉! ]
𝑑𝑡
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𝑑[𝑉! ]
= 𝑘! 𝑇! + 𝑘! 𝑘!! 𝑇! − 𝑘! [𝑉! ]
𝑑𝑡

(3.5)

	
  	
  
	
  

	
  
Figure 3.2. HIV Dynamic Model (based on Wu and Zhang 2010). In the presence of HIV,
uninfected CD4+ T-cells can be infected by drug-sensitive (black dots) or drug-resistant (red
dots) virus resulting in infected CD4+ T-cells. These infected T-cells then proceed to produce and
release additional virus. Mutation in the drug-sensitive HIV can also result in new drug-resistant
HIV. Highly Active Antiretroviral Therapy (HAART), which consists of two types of reverse
transcriptase inhibitors (teal boxes and blue parallelograms) and a protease inhibitor (blue
triangles), inhibits the ability of HIV to reproduce in infected cells rendering the virus inactive.
All model components are subject to degradation pathways.
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In this model, [Tc] represents the concentration of uninfected CD4+ T-cells, [Ts]
represents the concentration of CD4+ T-cells infected by drug-sensitive HIV, [Tr]
represents the concentration of CD4+ T-cells infected by drug-resistant HIV, [Vs]
represents the drug-sensitive HIV, and [Vr] represents the drug-resistant HIV. Uninfected
CD4+ T-cells are constitutively produced (described by zero-order reaction parameter k1)
and are subject to degradation (k2). They can also be lost due to infection by drugsensitive (k9) and drug-resistant (k10) HIV. Infection by drug-sensitive HIV is modulated
by the presence of reverse transcriptase inhibitors (RT). CD4+ T-cells infected by drugsensitive HIV are the result of the infection of uninfected cells with drug-sensitive HIV
and can be lost to degradation (k3). CD4+ T-cells infected by drug-resistant HIV are the
result of the infection of uninfected cells with drug-resistant HIV and can also be lost to
degradation (k4). Drug-sensitive HIV is produced by drug-sensitive HIV infected T-cells
(k5) and is subject to degradation (k7). The production of new drug-sensitive HIV can be
impeded by protease inhibitors (PI) and mutation to a drug-resistant strain (k11). Finally,
drug-resistant HIV is produced by drug-resistant HIV infected T-cells (k6) and is also
subject to degradation (k8). Drug-resistant HIV levels also increase when drug-sensitive
HIV mutates to a drug-resistant strain. Both reverse transcriptase inhibitors and protease
inhibitors are present in HAART. The model parameters are listed in Table 3.2.
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Table 3.2. HIV Dynamic Model Parameters (Wu and Zhang 2010)	
  
Parameter	
  
Description	
  
k1	
  
Growth rate of T cells	
  
k2	
  
Death rate of T cells	
  
k3	
  
Death rate of T cells infected by sensitive virus	
  
k4	
  
Death rate of T cells infected by resistant virus	
  
k5	
  
Growth rate of sensitive virus	
  
k6	
  
Growth rate of resistant virus	
  
k7	
  
Natural death rate of sensitive virus	
  
k8	
  
Natural death rate of resistant virus	
  
k9	
  
Natural death rate of T cell infection by sensitive virus	
  
k10	
  
Natural death rate of T cell infection by resistant virus	
  
k11	
  
Mutation rate of virus	
  

Base Value	
  
10 cells/(mm3*day)	
  
0.01/day	
  
0.02/day	
  
0.01/day	
  
8/day	
  
8/day	
  
30/day	
  
30/day	
  
3*10-4 mm3/(virons*day)	
  
5*10-5 mm3/(virons*day)	
  
0.2	
  

	
  

An optimal treatment will maintain the uninfected T-cell levels above 500
cells/mm3 and the combined HIV titer below 50 virons/mm3 while minimizing the
amount of treatment administered. The bounds on the Tc and HIV titers are taken from
Office of AIDS Research Advisory Council’s definition effective HIV treatment (Panel
2009). The purpose of minimizing the total treatment dosage is to reduce the subject’s
risk of suffering dose-associated toxicities. Genetic algorithms have been used as a tool to
optimize HAART regimens for theoretical subject (Castiglione et al. 2007). Genetic
algorithms were therefore programmed using each selection method under investigation
to optimize HAART treatment for HIV in the theoretical subject. The fitness of each
chromosome was calculated by summing the penalties incurred by both failing to keep
the Tc levels and HIV titers outside the respective bounds and by treatment dosage. Each
chromosome consisted of 200 daily dosages of HAART ranging between 0% and 100%
of full HAART dosage. The objective of each algorithm was to minimize the
chromosome score. For each selection strategy, ten trials were conducted. The algorithms
were carried out over 2,000 generations and the treatment score results as well as the
effect of each treatment on the HIV model variables were compared to determine which
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algorithm provided the best treatment strategy.

3.3 Results
3.3.1 Function Tests
Utilization of the Elite Variant (EV) selection method resulted in significantly
faster convergence to the global optima of Function Tests 1-4 as shown in Figures 3.3a-d.
Although convergence to the global optimum never occurred for Function Test 5 after
25,000 generations, the use of Elite Variant selection yielded a significantly better
scoring result, shown in Figure 3.3e.
Function Test 1 (see Figure 3.3a) displayed convergence of the genetic algorithms
using EV and Elite selection to the global optimum, which is a string of 0’s with a
chromosome score of 0. Use of EV selection resulted in convergence to the global
optimum in all 50 EV trials after 21,000 generations, with 98% of trials converging by
generation 14,500. Using Elite selection, 94% of trials reached the global optimum after
25,000 generations. In comparison to the EV method, 0% of Elite trials reached the
global optimum after 14,500 generations. The Tournament, Proportional, and Linear
Ranking selection algorithms all quickly reached local optima at chromosome scores of
approximately 600, 1,800, and 40,000 respectively (Linear Ranking data not shown) and
were not able to escape the local optima by generation 25,000. None of the trials using
these selection methods resulted in the optimal solution.
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Figure 3.3. Evolution of Solutions in Function Tests. Genetic algorithms programmed to solve
Function Tests 1 (A), 2 (B), 3 (C), 4 (D), and 5 (E) were carried out over 25,000 generations. The
best scoring chromosome was plotted every 50 generations for genetic algorithms using EliteVariant (blue), Elite (red), Tournament (green), Proportional (gold), and Linear Ranking (brown)
selection methods. For each test, 50 trials were carried out per algorithm. It was observed that the
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genetic algorithms using Elite Variant (EV) selection converged to better scoring solutions in less
time than genetic algorithms using other selection methods. It was also observed that genetic
algorithms using Tournament, Proportional, or Linear Ranking selection were not able to escape
local optima by generation 25,000 for all Function Tests. Note: The error bars attached to the EV
selection plot in Figure 3.3c extend beyond the graphical space and are therefore left unbounded.
The error incurred in these trials reached values below zero and cannot be displayed on a
logarithmic scale.

	
  
Function Test 2 (see Figure 3.3b) displayed a similar result to that of Function
Test 1 as the genetic algorithms utilizing EV and Elite selection converged to the global
optimum, while the genetic algorithms utilizing Tournament, Proportional, and Linear
Ranking selection quickly reached local optima at approximate chromosome scores of
150, 350, and 550 respectively from which they were not able to escape by generation
25,000. The Linear Ranking selection algorithm, because it placed more weight on
chromosome rank rather than chromosome score, quickly lost the top scoring
chromosomes from the early generations and reached an inferior local optimum as
compared to its starting point. Genetic algorithms using EV selection reached the global
optimum after 18,500 generations in all 50 trials. Similarly, genetic algorithms using
Elite selection reached the global optimum after 21,500 generations in all 50 trials. A
more telling comparison is that 90% of the EV algorithms reached the optimal solution
after 13,000 generations whereas only 24% of the algorithms using Elite selection
reached the global optimum at this time.
The scale of chromosome scores in Function Test 3, as can be seen in Figure 3.3c,
provided a challenge to each selection method. 40% of the genetic algorithm trials using
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EV selection were able to find the global optimum after 25,000 generations. No other
genetic algorithm trials using other selection methods were able to find the global
optimum by generation 25,000. Likewise, EV algorithms on average yielded a
significantly better result after 25,000 generations than did algorithms using the other
selection methods. Recalling that lower scores are desirable in this case, the average
results after 25,000 generations were 102.5 ± 93.0 using EV selection, 582.6 ± 251.1
using Elite selection, 1.3*106 ± 1.9*105 using Tournament selection, 5.2*106 ± 7.0*105
using Proportional selection, and 3.5*108 ± 6.1*107 using Linear Ranking selection.
Function Test 4 also yielded a result similar to that of Function Tests 1 and 2, as
can be seen in Figure 3.3d. Genetic algorithms using Tournament, Proportional, and
Linear Ranking selection again reached local optima at approximately 580, 1,800, and
3,900 respectively, from which they were not able to escape by generation 25,000. Again,
the Linear Ranking selection algorithm as well as the Proportional selection algorithm by
maintaining too broad a search of the solution space quickly lost the top scoring
chromosomes of the early generations and reached local optimums at chromosomes
scores greater than that of the best early generation chromosome scores. All algorithm
trials using EV and Elite selection converged to the global optimum by generation
25,000. In contrast, at generation 11,500, 92% of genetic algorithm trials using EV
selection had converged to the global optimum while no trials using Elite selection had
converged. In fact, the average chromosome score of a population in an algorithm using
Elite selection at generation 11,550 was 10.5 ± 3.0.
Function Test 5 displayed the most peculiar behavior of all of the Function Tests,
as can be seen in Figure 3.3e. The results of this test showed that genetic algorithms using
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Elite, Tournament, Proportional, and Linear Ranking selection converged along a very
similar path while genetic algorithms using EV selection converged quickly to a more
optimal solution. The average best solutions after 25,000 generations for algorithms using
each selection method were 1.53 ± 0.055 for EV selection, 1.71 ± 0.067 for Elite
selection, 1.72 ± 0.062 for Tournament selection, 1.69 ± 0.065 for Proportional selection,
and 1.70 ± 0.061 for Linear Ranking selection. No trials were able to reach the global
optimum in this test.

3.3.2 Satisfiability Test
Implementation of a satisfiability test, shown in Figure 3.4, also demonstrated the
ability of the EV selection method to facilitate the convergence of a genetic algorithm to
an optimal solution. Genetic algorithms using Tournament, Proportional, and Linear
Ranking selection yielded results at local optimum chromosome scores of approximately
450, 1,500, and 3,400 respectively. Again, algorithms using these selection methods were
not able to escape these local optima by generation 25,000. Conversely, algorithms using
EV selection converged to the global optimum by generation 16,000 in all cases with
90% reaching this optimum by generation 12,500.
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Figure 3.4. Evolution of Satisfiability Test Solutions. Scores of the most fit chromosomes were
plotted every 50 generations for genetic algorithms using Elite Variant (EV) selection (blue),
Elite selection (red), Tournament selection (green), Proportional selection (gold), and Linear
Ranking selection (brown) to solve a satisfiability problem. The algorithm was carried out for
25,000 generations (A), with the fastest convergence occurring in the first 4,000 generations (B).
Each algorithm was carried out 50 times. The genetic algorithm using EV selection was able to
solve the satisfiability problem in fewer generations than any genetic algorithm using another
selection method. Genetic algorithms using Tournament, Proportional, or Linear Ranking
selection were not able to solve this satisfiability problem in 25,000 generations.	
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Genetic algorithms using Elite selection also exhibited desirable convergence,

with 96% of the trials reaching the global optimum by generation 25,000. Elite selection
trials again did not converge as quickly as EV selection trials. In comparison, at
generation 16,000 when all EV selection trials had converged, only 40% of the Elite
selection trials had converged to the global optimum.

3.3.3 HAART Optimization
Genetic algorithms using the selection strategies under investigation were
implemented to optimize Highly Active Antiretroviral Therapy (HAART) regimens for a
theoretical Human Immunodeficiency Virus (HIV) subject. Figure 3.5 shows the fitness
of the best scoring chromosomes plotted over 2,000 generations for each case. The
objective once again was to minimize the chromosome score. Genetic algorithms using
EV and Elite selection produced better scoring chromosomes in each generation as
compared to genetic algorithms using Tournament, Proportional, and Linear Ranking
selection. In fact, the Proportional selection and the Linear Ranking selection algorithms
once again reached local optimums at scores above that of the best scoring early
generation chromosomes due to too broad a search of the solution space. After 2,000
generations, the genetic algorithm using EV selection produced an average top scoring
chromosome score of 2,475.23 ± 18.42 while the genetic algorithm using Elite selection
produced an average top scoring chromosome score of 2,523.34 ± 22.77. In comparison,
the average top scoring chromosome score using EV selection was, within error, the same
as the top scoring chromosome using Elite selection between generations 0 and 1,700.
Even so, the EV selection algorithm maintains a clear advantage over the Elite selection
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algorithm in regards to convergence time as the average result of the Elite selection
algorithm after 2,000 generations was obtained by the EV selection algorithm after only
150 generations.

	
  
Figure 3.5. Evolution of Highly Active Antiretroviral Therapy (HAART) for Treatment of
Human Immunodeficiency Virus (White and Srivastava 2011). Genetic algorithms using EV
(blue), Elite (orange), Tournament (red), Proportional (green), and Linear Ranking (brown)
selection were programmed to optimize HAART over 2,000 generations for treatment of a
theoretical case of HIV. The score of the best scoring treatment was plotted every 50 generations.
Each algorithm was carried out 10 times. The genetic algorithm using EV selection was able to
evolve a more optimal HAART regimen after 2,000 generations than the genetic algorithms using
the other selection methods. In fact, the average score of the top scoring treatment as determined
using Elite selection after 2,000 generation was equal to the average score of the top scoring
treatment as determined using EV selection after only 150 generations.
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Figure 3.6. Optimized Highly Active Antiretroviral Therapy (HAART) Regimens (White
and Srivastava 2011). After 2,000 generations, the top scoring treatment was taken from each
genetic algorithm and used to treat a theoretical case of HIV. The HAART regimen as determined
by the genetic algorithm using EV selection (A, blue) suggested on average a daily dose of 70%
from day 0 to day 50 followed by a decrease to a daily dose of 50% from day 50 to day 200 with

	
  

42	
  

some fluctuation in dose. Similarly, the HAART regimen as determined by the genetic algorithm
using Elite selection (B, red) suggested on average a daily dose of 90% from day 0 to day 50
followed by a decrease to a daily dose of 50% from day 50 to day 200 with some fluctuation in
dose. HAART regimens as determined by genetic algorithms using Tournament (C, green),
Proportional (D, gold), and Linear Ranking (E, brown) selection suggest a highly variable dosage
from day to day over the course of the 200-day treatment period.

	
  
The HAART regimens evolved using genetic algorithms with different selection
strategies are shown in Figures 3.6a-e. It was observed that HAART dosages optimized
using Tournament, Proportional, and Linear Ranking selection fluctuated drastically each
day. This result demonstrated the inability of the genetic algorithms using these selection
methods to home in on an optimum HAART regimen. Conversely, HAART dosages
optimized using EV and Elite selection were more consistent. In general, the HAART
regimen optimized using EV selection resulted in daily dosages of 70% from day 0 to day
50 and daily dosages of 50% from day 50 to day 200 with some variation. The HAART
regimen optimized using Elite selection resulted in the same pattern with the exception of
daily dosages of 90% from day 0 to day 50. The percentage of the total possible HAART
dosage administered over 200 days was determined to be 53.28% using EV selection,
54.70% using Elite selection, 56.08% using Tournament selection, 55.47% using
Proportional selection, and 44.85% using Linear Ranking selection.
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Figure 3.7. Effect of Optimized HAART on HIV Model Variables (White and Srivastava
2011). HAART as determined by genetic algorithms using EV (blue), Elite (red), Tournament
(green), Proportional (gold), and Linear Ranking (brown) selection was applied to the HIV model
over a 200 days period. The effects of HAART on uninfected T-cell (A), drug-sensitive HIV
infected T-cell (B), drug-resistant HIV infected T-cell (C), drug-sensitive HIV (D), and drugresistant HIV (E) levels are shown. HAART as determined using EV, Elite, and Tournament
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selection resulted in a similar effect on all model variables with the exception of drug-sensitive
HIV being less controlled using HAART determined using Tournament selection. HAART
determined using Linear Ranking selection resulted in less control of the infected and a slower
rebound of the uninfected T-cell levels. Conversely, less drug-resistant HIV and drug-resistant
HIV infected T-cells accumulated in this case.

	
  
Figures 3.7a-e show the results of each HAART regimen on the model variables.
In Figure 3.7a, it was observed that HAART regimens produced by genetic algorithms
using EV, Elite, and Tournament selection strategies resulted in an increase in uninfected
T-cell (Tc) levels to the goal of 500 cells/mm3 by day 60. The HAART regimens
produced by genetic algorithms using Proportional and Linear Ranking selection also met
this goal, but at a later time. HAART determined by Proportional selection met the Tc
goal around day 75 while HAART determined by Linear Ranking selection met the same
goal around day 200. Figures 3.7b and 3.7c display a similar result for drug-sensitive (Ts)
and drug-resistant (Tr) HIV infected T-cells for cases when HAART was determined by
genetic algorithms using EV, Elite, Tournament, and Proportional selection. HAART
determined by a genetic algorithm using Linear Ranking selection resulted in a higher
concentration of drug-sensitive and a lower concentration of drug-resistant cells.
Following these results, HIV infection was less controlled by the HAART regimen
determined using Linear Ranking selection, as illustrated in Figures 3.7d and 3.7e.
Indeed, Figure 3.7d showed that all HAART regimens resulted in fluctuation of drugsensitive virus as a result of fluctuation in treatment dosages. Because treatment dosage
was more variable in Linear Ranking, Proportional, and Tournament selection generated
HAART, Vs titers fluctuate to a greater extent and less control is maintained over levels
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of drug-sensitive virus.

3.4 Discussion
The results of the Function Tests, Satisfiability Test, and HIV/HAART Test
clearly demonstrate the advantages of using Elite Variant selection when using genetic
algorithms to solve these problems. In all cases, algorithms using EV selection were able
to arrive at better scoring solutions in a smaller amount of time, making it an attractive
option when trying to quickly determine or estimate the solution of a complex problem.
EV selection demonstrates through these tests that it is not only able to converge
quickly to an optimum, but it is also able to completely bypass local optima that other
selection strategies spend significant time attempting to escape. Both Elite and EV
selection balance the broad probing of the solution space exhibited by Tournament,
Proportional, and Linear Ranking selection with a mechanism for keeping wellperforming genetic material while effectively pursuing the objective function. EV
selection takes this methodology one step further by forcing the population quickly to a
local optimum while also giving the algorithm a way to escape the local optimum. The
algorithm reverts back to the Elite selection strategy while at a local optimum and then
switches back to EV selection upon escape facilitating “leaps” in the evolution of the
population.
In the examples of the Function Tests and the satisfiability test, the capabilities of
EV selection are demonstrated. Following these results, the HIV/HAART test
demonstrated the potential of EV selection in genetic algorithms to arrive at better
solutions in a shorter period of time with the result being a more optimal treatment for a
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real disease. If a particular HIV subject could be modeled by a series of differential
equations describing the key variables at play, a genetic algorithm using EV selection
would be able to offer a HAART regimen that would more effectively treat that subject
according to the constraints on uninfected T-cell levels, combined HIV titers, and
HAART dosage. In the theoretical case presented in this paper, the HAART regimen
produced by the genetic algorithm using EV selection was able to elevate the
concentration of uninfected T-cells as quickly as the Elite, Tournament, and Proportional
HAART regimens. It was also able to control the combined HIV titers as well as these
other HAART regimens. What sets the EV HAART regimen apart from these other
treatments is that it was able to achieve these results while administering a smaller dosage
of HAART reducing the subject’s exposure to the drug and chance of suffering doseassociated toxicities. Conversely, the Linear Ranking HAART regimen administered a
smaller amount of HAART than did the EV HAART regimen. In doing so, the Linear
Ranking HAART regimen was not able to bring the uninfected T-cell levels back up to
500 cells/mm3 nearly as fast as the EV HAART regimen was able to. It also maintained
far less control over the level of HIV virus. Because of these behaviors, the EV HAART
regimen was the best scoring of all the HAART regimens.
As a result, Elite Variant selection, when used as the selection method in genetic
algorithms, can result in better, faster solutions. It is advised, as any problem contains its
own subtleties, that all selection methods should be tested when using a genetic algorithm
to evolve a solution to a problem in case that particular problem is well suited to one of
the other commonly used selection methods. A benefit of this algorithm, besides
providing more accurate solutions to complex problems, is that the process of carrying
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out genetic algorithms will be less computationally intensive thereby expanding a
researcher’s capability to evolve solutions to more complex problems as well as carry out
a greater amount of trials in a smaller amount of time. Applications of this algorithm will
be beneficial in multiple domains in which genetic algorithms are useful, ranging from
traditional optimization to classification technology in fields encompassing medicine,
logistics, finance, etc.
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CHAPTER 4
OPTIMIZING HIV-1 TREATMENT VIA A SYSTEMS BIOLOGY APPROACH
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4.1 Introduction
	
  

A major goal of developing mathematical models of diseases is to understand the

underlying pathology. One of the benefits arising from such a quantitative understanding
is the potential to develop and optimize treatment strategies that maximize health benefits
while minimizing secondary toxicity effects.
It is possible to capitalize upon recent advances in systems biology to implement
this strategy. By systematically perturbing the biological network underlying the disease,
it is possible to monitor the gene, protein, and informational pathway responses; integrate
these data; and ultimately, formulate mathematical models describing the structure of the
system (Ideker et al. 2001, van der Greef et al. 2004). Systems biology provides an
impactful foundation for analysis of the comprehensive datasets that are needed in order
to develop robust kinetic models. The technology also permits verification against
experimental results. Ideally, the resulting model may be used to predict progression of
the disease (Bogojeska et al. 2010, Burg et al. 2009, Castiglione and Paci 2010, Degon et
al. 2008, de Sousa et al. 2010, Guedj et al. 2010, Hoffmann et al. 2002, Itakura 2010,
Perelson et al. 1996, Smith and Ribeiro 2010, Srivastava et al. 2002, von Kleist et al.
2010, Wendelsdorf et al. 2010, Yang et al. 2007). It is also possible to identify, develop,
and optimize treatment strategies in a mathematically rigorous fashion.
HIV-1 is a key disease that has received significant interest from the modeling
community (Aviran et al. 2010, Bonhoeffer et al. 1997(b), Nowak and May 2000,
Perelson et al. 1996, Perelson 2002). In recent years, HIV-1 treatments have significantly
reduced AIDS-related mortalities and have enhanced long-term disease control (Dybul et
al. 2001, Fagard et al. 2003, Powderly 2002, Ruiz et al. 2001). These benefits have been
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realized in large part via use of highly active antiretroviral therapy (HAART) in clinical
practice. The HAART strategy consists of treating the disease with a combination of
antiretroviral drugs.

Despite advances in efficacy over prior generation treatments,

HAART is associated with risk of serious side effects that include cardiovascular disease
(Domingos et al. 2009), nephrotoxic effects (Izzedine et al. 2009), and oral toxicities
(Nittayananta et al. 2010). Up to 16% of patients require modification or discontinuation
of their HAART regimen due to drug-related toxicities (Mocroft et al. 2005).
In an attempt to reduce incidence and severity of these side effects, clinical trials
have explored various methods of reducing drug exposure by structured treatment
interruption (STI). In STI, HAART is discontinued and resumed at pre-defined time
intervals in an effort to control the viremia while concurrently administering the lowest
possible dose of HAART in order to reduce toxicity (Castiglione et al. 2007, Dybul et al.
2001, El-Sadr et al. 2006, Fagard et al. 2003, Garcia et al. 2001, Kilby et al. 2000, Ortiz
et al. 2001, Ruiz et al. 2001). Published STI regimens that were analyzed include 8
weeks on – 2 weeks off (8w/2w) STI (Fagard et al. 2003) and 1 week on – 1 week off
(1w/1w) STI (Castiglione et al. 2007, Dybul et al. 2001). These studies and their
outcomes are listed in Table 4.1. Other STI regimens which have been studied include 1
month on – 1 month (1m/1m) off STI (Ortiz et al. 2001) and SMART STI (El-Sadr et al.
2006). Unlike standard STI that discontinues and resumes treatment at pre-defined timepoints, SMART STI prescribes the initiation of treatment when the CD4+ T-cell
concentration falls below 250,000 cells/mL and the discontinuation of treatment when the
CD4+ T-cell concentration recovers to 350,000 cells/mL.
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Despite their theoretical promise STI strategies have been largely unsuccessful.
Thus there remains a need to define safe and effective “optimal” HAART strategies for
large and diverse clinical cohorts. Treatment that is optimized to an individual may
permit more effective control of that individual's HIV disease while concurrently
reducing total HAART exposure and associated toxicities. To this end the goal of this
study was to design an optimized dosing schema, based on an established mathematical
model of HIV, for minimizing HAART exposure while maintaining durable virologic
suppression. Results were compared to clinically reported results of standard HAART
and STI dosing regimens to further validate the conceptual framework.

Table 4.1. Total HAART Dosage Prescribed By Each Treatment Regimen
Description of Treatment
HAART Administered
% of Subjects Achieving Viral
Regimen
(% of maximum
Suppression After Treatment
dosage)
Period
Optimized HAART
78.1%
N/A
Standard HAART
100.0%
90%
1 week on – 1 week off STI
50.0%
80%
8 weeks on – 2 weeks off STI
83.3%
77.5%

4.2 Methods
4.2.1 Model Selection
There is a substantive literature pertaining to development of models describing
HIV-1 (Aviran et al. 2010, Bonhoeffer and Nowak 1997, Bonhoeffer et al. 1997(b),
Bonhoeffer et al. 2000, Burg et al. 2009, Herz et al. 1996, Liang et al. 2010, Nowak et al.
1997, Nowak and May 2000, Perelson et al. 1996, Perelson 2002, Prosperi et al. 2009,
Ribeiro et al. 2010, von Kleist et al. 2010, Wu et al. 2010, Wu and Zhang 2010, Zeng
and Yang 2010). The HIV-1 dynamic model of Perelson and Nelson (Perelson and
Nelson 1999) shown in Figure 4.1 was selected as the basis for this work because it
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Figure 4.1. HIV Dynamic Model (based on Perelson and Nelson 1999). In the presence of
HIV, uninfected CD4+ T-cells can be infected by HIV (black dots) resulting in infected CD4+ Tcells. The infected T-cells then proceed to produce and release additional virions. Highly Active
Antiretroviral Therapy (HAART), which consists of nucleoside analog and non-nucleoside
reverse transcriptase inhibitors (teal boxes and blue parallelograms) and a protease inhibitor
(green triangles), inhibits the ability of HIV to reproduce in infected cells rendering the virus
inactive. All model components are subject to degradation pathways.

	
  
included the action of reverse transcriptase inhibitors and protease inhibitors, both of
which predominantly comprise HAART regimens. The model is quantitatively described
via a set of ordinary differential equations presented in Equations 4.1-4.3.

d [T ]
= k1 − k2 * T − k3 * (1 − RT ) * V * T
dt

(4.1)

d [TI ]
= k3 * (1 − RT ) * V * T − k 4 * TI
dt

(4.2)

d [V ]
= k 4 * k5 * (1 − PI ) * TI − k6 * V
dt

(4.3)
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In this model, T represents the concentration of uninfected CD4+ T-cells, TI

	
  

represents the concentration of CD4+ T-cells infected by HIV, and V represents the HIV
concentration. Uninfected CD4+ T-cells are constitutively produced (described by zeroorder reaction parameter k1) and are subject to degradation (k2). They can also be
depleted due to infection by HIV (k3). Infection by HIV is modulated by the presence of
reverse transcriptase inhibitors (RT). CD4+ T-cells infected by HIV are the result of the
infection of uninfected cells with HIV (k3) and can be lost to degradation (k4). HIV is
produced by HIV infected T-cells (k4, k5) and is also subject to degradation (k6). The
production of new, drug-sensitive HIV can be impeded by protease inhibitors (PI). The
average or baseline case parameters were derived from the literature (Perelson and
Nelson 1999) and are listed in Table 4.2.
	
  
Table 4.2. HIV Dynamic Model Parameters (Perelson and Nelson 1999)
Parameter

Description

Base Value

k1

Growth rate of T cells

10,000 cells/(mL*day)

k2

Death rate of T cells

0.01/day

k3

Infection of T cells by HIV

5*10 mL/(copies*day)

k4

Death rate of T cells infected by virus

0.5/day

k5

Burst size/Virions released by lysed cell

16.75 copies/cell

k6

Natural death rate of sensitive virus

3.1/day

-7

	
  
	
  

The Perelson and Nelson model accounted for two types of CD4+ T-cells

(uninfected, and infected) and a general strain of HIV. These sub-populations of CD4+ Tcells as of yet cannot be measured clinically and therefore the specific concentrations of
these variables as reported by the model cannot be verified clinically. The predictions for
each of these three variables made by the model were taken to be a reasonable
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approximation of HIV infection. We anticipate the advances in technology that will allow
for the differentiation of these subpopulations of CD4+ T-cells in the clinical setting.
When applying HAART in this model, it was assumed that 50% of the dose
contained a protease inhibitor and the other 50% of the dose contained a mixture of two
reverse transcriptase inhibitors; this assumption is consistent with most HAART dosing
recommendations (Panel 2009). In the model this was described by setting both RT and
PI equal to 0.45, thereby quantifying the inhibition of the pathways describing HIV
infection and propagation associated with these drugs. In this study, HAART dosages
were reported daily on a scale that ranged from 0% (null dose) to 100% (full dose). A full
dose (100%) in this case refers to the maximum dosage that can be administered.
Outcomes evaluated for each dosing strategy was the range of successful treatment
coverage (ROC), Equation 4.4, defined as the ability of the treatment to suppress the HIV
titer below 50 copies/mL at the 48-week time point at the conclusion of the simulation.
The 48-week time frame was chosen as it is used as a common benchmark for
determining the efficacy of a HIV treatment regimen (Eron et al. 2006, Madruga et al.
2007, Sanne et al. 2003).

𝑅𝑂𝐶 =   

#!"#$%&'()*+,!!"! !"# !!!"!""#$ !!"!"#$%&/!"
!"#$%#!"#$%&'()*+,!!"#

(4.4)

4.2.2 Optimization of Highly Active Antiretroviral Therapy (HAART)
A 48-week (336-day) HAART regimen was optimized for the average subject
based on Equations 4.1 – 4.3 using the gPROMS software. gPROMS employs both
single-shooting and multiple-shooting dynamic optimization methods to converge upon
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an optimal solution. The average subject's biochemical indicators, described by Equations
4.1-4.3, were allowed to equilibrate after being initiated from the initial conditions listed
in Table 4.3. The equilibrium values for each of the 3 variables, listed in Table 4.4, were
used as the initial conditions for HAART optimization. The optimized HAART regimen
was described by a list of daily HAART dosages ranging from 0% to 100%. The
objective function, defined by Equation 4.5, was minimization of the total dosage of
HAART. The constraint imposed was that the HIV titer remained below 50 copies/mL.
The bound on the HIV titer was chosen based upon the detection limit and target for
suppression of HIV RNA (Panel 2009).

(4.5)

	
  
Table 4.3. Average Subject's Initial Conditions, Pre-Treatment
Variable

Initial Condition

T

1,000,000 cells/mL

TI

0 cells/mL

V

100 copies/mL

	
  
Table 4.4. Initial Conditions at the Initiation of Treatment Optimization
Variable

Initial Condition

T

462,838 cells/mL

TI

223,368 cells/mL

V

557,195 copies/mL
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4.2.3 Comparison of Optimized HAART to Standard HIV-1 Treatments Administered to
Computer-Generated Cohorts
Seven groups of 1,000 HIV positive subject computer-generated cohorts with
different degrees of inter-patient variation were simulated. Each computer-generated
cohort was comprised of 1,000 computer-generated (in silico) subjects. Specifically,
parameter values in the first group were allowed to vary randomly by as much as 4%
from the baseline. Parameter values in the remaining six groups were allowed to vary by
as much 7%, 10%, 20%, 25%, 30%, or 40%. Smaller percentage parameter variation
indicated a more homogeneous population, while higher percentage parameter variation
indicated a cohort with a more diverse immune response. Each computer-generated
cohort was treated with standard and STI HAART regimens, including consistent
maximum or standard HAART dosage, an optimized HAART regimen, 8w/2w STI
(Fagard et al. 2003), and 1w/1w STI (Castiglione et al. 2007, Dybul et al. 2001). Ten in
silico cohorts were evaluated at each measure of inter-patient variation for each of the
treatment regimens. Simulated treatment was initiated when the uninfected CD4+ T-cell
count fell below 500,000 cells/mL. Standard HAART and optimized HAART were
simulated for 48 weeks after its initiation. In order to compare results in this in silico
study directly to past clinical trials, 8w/2w STI was simulated for 40 weeks (Fagard et al.
2003) and 1w/1w STI was simulated for 68 weeks (Dybul et al. 2001). Subjects enrolled
in these clinical trials had undetectable ([HIV] < 50 copies/mL) viral loads. To closely
replicate these trials, in silico subjects were treated with full treatment until the
concentration of HIV fell below 50 copies/mL, after which the STI was initiated. The
same method was used to simulate the optimized HAART regimen.
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In all simulations and if the subject's uninfected CD4+ T-cell count did not call for
the initiation of treatment after two simulated years, the simulation of that subject was
terminated with an output that treatment was not needed. The range of successful
treatment coverage (ROC), defined as the ability of the treatment to suppress the HIV
titer below 50 copies/mL by the end of the 48-week treatment cycle, was calculated for
each test case. The results were compared to the ROC calculated for each cohort using
the two optimized HAART regimens.

4.3 Results
4.3.1 Optimal HAART Dosage for Base Case
Optimization of the HAART regimen for the average subject was based upon the
objective function, described in Methods, where total HAART dosage over the 48-week
treatment period. The resulting predicted treatment strategy is shown in Figure 4.2. Full
dosage (100%) was prescribed for the first 31 days of the treatment regimen. The
concentration of HAART prescribed then rapidly decreased, with dosages between 70%
and 78% of full dosage prescribed between day 42 and day 324. HAART was prescribed
at a concentration of 68.8% of full dosage for the last 10 days of the regimen. The total
amount of HAART prescribed over the 48 weeks was 78.1% of maximum HAART
dosage.
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Figure 4.2. HAART Treatment Strategy Optimized for the Average Subject. Daily dosages
of HAART are plotted over 48 weeks (336 days) as percentages of the maximum HAART
dosage. HAART was optimized to minimize the total HAART dosage administered subject to the
constraint that the subject’s viral load remains below 50 virons/mL. Total HAART dosage over
the 48-week period prescribed by the optimized treatment regimen is 78.1% of the total possible
HAART dosage.

4.3.2 Comparison of HAART Strategies via Simulation Studies
The range of successful treatment coverage (ROC) was calculated for multiple
simulated cohorts of subjects receiving simulated standard treatment, optimized
treatment, 1w/1w STI, and 8w/2w STI. Successful treatment in this modeling was
defined as the ability of the treatment to suppress the HIV titer below 50 copies/mL at the
48-week time point. Table 4.1 lists the total amount of HAART administered by each
treatment regimen.
The ROC that resulted by modeling the standard HAART dosage in ten in silico
cohorts of 1,000 in silico subjects decreased from 100% to 75.15% ± 1.68% as the
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variation in HIV model parameters increased, as shown in Figure 4.3. When optimized
HAART dosing was used to treat each computer-generated cohort, ROCs generally
decreased as variation in HIV model parameters increased. 8w/2w STI ROCs decreased
as variation in HIV model parameters increased also. Conversely, ROCs observed for the
1w/1w STI increased as the variation in HIV model parameters increased.
The different treatment regimens delineated different patterns of coverage as
simulated inter-patient variation increased. For example, 1w/1w STI showed a pattern of
increasing ROC with increasing variability among subjects, while conversely, optimized
HAART, standard HAART, and 8w/2w STI showed a pattern of decreasing ROC. Also,
the generation of “extreme cases” or computer-generated subjects with the ability to be
strongly resistant or highly susceptible to infection was more likely to occur as interpatient variation was increased. As population variability increased, treatment strategies
that provided smaller overall drug exposure, such as the 1w/1w STI, were more
successful due to the increased number of individuals better able to deal with the disease.
Treatment strategies that uniformly provided higher overall drug exposures, such as
standard HAART, had lower ROCs in cohorts of greater inter-patient variability. The
cause of the lower ROCs was because in silico subjects who were highly susceptible to
infection were more likely to be generated, and as a result even the higher doses of
HAART were not able to control their infection. ROCs observed for optimized HAART,
which had the tendency to more precisely dose subjects, were found to respond much like
standard treatment to increases in inter-patient variation.

	
  

60	
  

Figure 4.3. HAART Range of Coverage for in silico Cohorts Using Standard and
Customized Treatment. The range of coverage, or percentage of subjects successfully
responding to HAART, is plotted using each treatment strategy under investigation. HAART was
applied to in silico cohorts simulating variation among cohorts by varying the HIV dynamic
model parameters by 4%, 7%, 10%, 20%, 25%, 30%, and 40%. Successful treatment was
regarded as the ability of the treatment strategy to suppress a subject’s HIV titer below 50
copies/mL after 48 weeks.

4.3.3 Comparison of Simulation to Experimental STI Results
The ROCs observed by simulating inter-patient variation at 25% variability in the
model parameters were found to be most comparable to ROCs observed clinically, as
shown in Figure 4.4. Significant discrepancies in clinical ROCs and ROCs predicted
using the other measures of inter-patient variation were observed (data not shown). The
clinical range of successful treatment coverage for standard treatment, defined as those
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subjects whose HIV titer were undetectable after 48 weeks of treatment (Ledergerber et
al. 1999) was approximately 90%.

Figure 4.4. Comparison of Clinical Range of Coverage (ROC) to in silico ROC. The clinical
(ROC), or percentage of subjects successfully responding to HAART, pertaining to 2 standard
treatment interruption (STI) studies (Dybul et al. 2001, Fagard et al. 2003) and standard treatment
(Ledergerber et al. 1999) was compared to in silico ROCs predicted by this study. The best
results were observed when inter-patient variation was simulated by 25% variation in the HIV
model parameters. The in silico ROC describing the success of optimized HAART was found be
greater than that of 1 week on – 1 week off treatment and less than that of full and 8 weeks on - 2
weeks off STI.

The 8w/2w STI was predicted by our study to provide a high ROC. In the clinical
study, subjects were required to have an undetectable viral load ([HIV] < 50 copies/mL
for 6 months prior to study) and a CD4 count of 300,000 cells/mL in order to participate
in the trials (Fagard et al. 2003). In the published clinical results, this strategy provided a
77.5% ROC after 40 weeks of treatment. For this STI strategy, using a simulated inter	
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patient variation of 25% in the model parameters, the ROC predicted by the simulation
(82.34% ± 1.22%) was very close to the ROC found clinically (77.5%).
The 1w/1w STI strategy was predicted to provide the lowest ROC. In the clinical
study carried out by Dybul et al (Dybul et al. 2001), ten subjects were enrolled that had
previously responded well to continuous treatment and entered with HIV RNA levels
below 50 copies/mL and CD4+ T-cell counts above 300,000 cells/mL. Eight of the ten
subjects who completed this study were observed to maintain an HIV titer below 50
copies/mL. It was also observed that small changes in adherence that increased the length
of the STI by a few days would lead to loss of control of the HIV titer. The ROC
calculated for the 1w/1w STI in the in silico cohorts was 46.41% ± 1.59% at a simulated
inter-patient variation of 25% in the HIV model parameters. The estimated ROC was
considerably lower than observed in the clinical proof-of-concept study (Dybul et al.
2001). This result could be explained by the fact that the patients in the clinical study
were described as those who had long-term control of plasma viremia and potentially had
not developed drug resistance during suboptimal antiviral therapy. As a result, these
individuals likely represented a subset of the in silico population with more robust
immune parameter values.

4.4 Discussion
Administration of standard HAART yielded the best range of successful treatment
coverage in each cohort while 1w/1w STI yielded a smaller range of coverage as has
been observed clinically. The 8w/2w STI treatment strategy provided a range of coverage

	
  

63	
  

approximating that of full HAART despite administration of 16.7% less drug than the
maximum; this finding was consistent with published clinical trial results in vivo.
Our study then evaluated if even lower levels of drug exposure could be
optimized in a computer-generated in silico population to retain suppression of HIV-1
viremia. A theoretical HAART regimen was optimized to minimize total HAART
administered for the average subject with the constraint that HIV-1 titers were to be
reduced below detectable limits. It was predicted to successfully treat almost 70% of a
computer-generated cohort while using a smaller amount of drug then the standard
HAART strategy or the 8w/2w strategy. Although ROCs yielded by optimized HAART
in the model were somewhat lower than those from maximum HAART dosage
administered under standard therapy, lower drug exposure prescribed by optimized
HAART implies less severe detrimental side effects. As a result, the potential exists for
improving the quality of life for a significant number of infected individuals. The range
of coverage results predicted by the in silico model demonstrate the ability of a systems
biology approach to optimize HAART for a theoretical subject as well as to predict the
effectiveness of a HAART treatment strategy for a theoretical cohort in advance of
exposing real human subjects to the hazards of a clinical trial. For example, the model
correctly predicted the limited ROC for most of the 1w/1w STI. The poor response to this
STI strategy as demonstrated in the modeling confirmed the results of the clinical trials
(Dybul et al. 2001). Thus, the approach utilized in this study has the potential to save the
significant time and resources expended on such clinical trials and avoid patient risk.
More importantly, such modeling could theoretically prevent patients from being put at
unnecessary risk during testing of therapeutic strategies unlikely to be effective. The

	
  

64	
  

relative ease and low-cost of testing novel treatment strategies with a systems biology
approach can potentially predict clinical outcomes in a large in silico cohort without the
time and resources required for completion of a clinical trial. As a result, the approach
described in this study may facilitate hypothesis generation and provide preliminary
exploratory analysis of new therapies or treatment strategies. It may furthermore assist in
the development of more focused and precise treatment improving the likelihood of
success and minimizing the likelihood of failure.
Our study also shows that “one-size-fits-all” treatment strategies fail to strike an
adequate balance between viral control and minimization of drug dosage. The standard
HAART regimen and the 8w/2w STI regimen prescribe more HAART and yield greater
ROCs. Even though these two treatment regimens have high ROCs, they also cause
increased risk of the treatment-associated side effects previously described. It is thus of
interest to develop HAART treatment strategies which balance the need to administer a
high enough concentration of HAART to control the infection while also administering a
small enough concentration of HAART to minimize risk of treatment-associated side
effects. This treatment strategy is consistent with modeling directed to an optimal
treatment strategy.
HAART in the current study was optimized to the average subject described by a
published model of HIV infection using an objective function calling for the
minimization of HAART dosage while maintaining the HIV titer below 50 copies/mL.
The same method of HAART optimization for the average subject could potentially be
applied to derive an in silico model using an individual subject’s CD4+ T-cell counts and
HIV-1 titers so as to optimize HAART for that individual subject. The modeling could
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theoretically be employed using data on an individual’s immune and viral kinetics to
optimize dosing for that particular individual. Appropriate modeling could identify those
patients who either require more than average antiretroviral drug exposure to maintain
virologic suppression, or those that could be safely provided lower levels of antiretroviral
drug exposure to reduce the incidence of medication-related adverse effects while still
maintaining durable virologic suppression. Patients identified at the extremes of
variability in the models could be candidates for individually modified and optimized
HAART strategies. As personalized medicine becomes more predominant, HAART
dosing that is customized to each individual patient based on individual kinetics will
likely be an important strategy to achieve maximal therapeutic efficacy with minimal
exposure to drug.
This study demonstrates the theoretic application of differing HAART strategies
by analyzing computer-generated in silico cohorts of subjects with a systems biology
approach. Such an approach can potentially predict greater treatment optimization and
reduced antiretroviral drug exposures. These systems biology methods analyzing HIV-1
treatment optimization and range of coverage prediction have significant implications for
the evolving field of personalized medicine. Using optimization of a daily HAART
regimen for treatment of HIV-1 in a computer-generated individual considered to be the
average individual as a model system, it was shown that the range of successful treatment
coverage of optimized HAART is much greater than that of most experimental STI
regimens. As a result there is considerable potential for systems biology to play an
integral role in optimizing the therapy of HIV-1 patients that administers the minimum
HAART dosage while still maintaining durable viral suppression. In addition, there are
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implications for the emerging field of personalized medicine. Specifically, the method
presented for HAART optimization may be applied to the individual patient based on
their specific physiological profile as characterized by their immune response kinetics.
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CHAPTER 5
DISCOVERY OF BIOCHEMICAL KINETICS AND MECHANISM USING A
GEP-BASED EVOLUTIONARY ALGORITHM
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5.1 Introduction
Mathematical models are used in nearly all industries to analyze data, make
predictions, and propose improvements based upon those predictions. Mechanistic
models describing chemical kinetic data sets are often defined by making assumptions as
to some model structure. Modeling of viral systems such as HIV-1, hepatitis B, and
others has been of great interest in the hopes of developing treatment strategies based
upon those models (Aviran et al. 2010, Bonhoeffer et al. 1997(a,b), Burg et al. 2009, de
Sousa and Cunha 2010, Guedj and Neumann 2010, Herz et al. 1996, Krishnan and Dixit
2011, Nowak and May 2000, Perelson 2002, Prosperi et al. 2009, Ribeiro and Bonhoeffer
2000, Srivastava et al. 2002, von Kleist et al. 2010, Wu and Zhang 2010, Zeng and Yang
2010) . Many models of various sizes and structures have been proposed for these
systems taking into account a wide range of biochemical species. Depending on the
species taken into account and their predicted relationships, the model behavior can vary
in response to any type of perturbation. The most comprehensive approach for
determining models describing biochemical systems would be to assume no prior
knowledge about the systems and the way that the species interact. In theory, it should be
possible to leverage an evolutionary algorithm to infer a mechanistic model describing
the species and their interactions, including some that may not be inherently obvious. The
resulting model could then be used to make predictions about the system, as well as to
test and optimize potential therapeutics.
Recently, work has been done on model generation from experimental data sets
without assuming any prior knowledge about system mechanism. Schmidt et al.’s Eureqa
formulize, a symbolic regression package that uses a genetic programming approach,
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quickly fits models to input data (Schmidt and Lipson 2009). Although these models
provide a good fit to experimental data, they often do not provide mechanistic
information as to how species in a biological system interact. Chattopadhyay et al.
developed an algorithm for inferring stochastic reaction mechanism from experimental
data (Chattopadhyay et al. 2013). This algorithm was successful at generating correct
mechanistic models on the algorithm’s error-complexity Pareto front, but some
knowledge of the system was required in order to select the correct model from a set of
potential models. A study by Bazil et al. provided a method for the reverse engineering of
biological networks by generating systems of ordinary differential equations from
experimental data (Bazil et al. 2011). This algorithm was successful in identifying
candidate pathways that were known to exist but also generated many false positive
pathways, as the algorithm was designed to minimize the number of false negative
pathways identified.
A common method used in these approaches is that of genetic programming.
Genetic programming is a type of evolutionary algorithm that generates programs or
models of varying size and structure while not assuming any pre-defined model structure.
The model is chosen by defining a set of functions (i.e. +, -, *, /), and a set of terminals
(i.e. variables, real numbers) as building blocks from which to construct equations (Koza
1992). Genetic programming works by generating a population of potential models of a
problem where each solution consists of the defined functions and terminals. The
potential models are ranked or scored based upon a defined fitness function. Models are
then selected, usually in proportion to their fitness score, to undergo recombination with
other models. The models may also undergo mutation to further increase population
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diversity. New models are incorporated with selected existing models, and the new
population of models is carried on to the next iteration where the algorithm repeats itself.
A few examples where genetic programming has been used to create models addressing
many different problems include the evolution of natural laws (Schmidt and Lipson 2009,
Iba 2008), computer vulnerability testing (Kayacik et al. 2011), prediction of longitudinal
dispersion coefficients in streams (Azamathulla and Ghani 2011), protein binding sites
(Bains et al. 2004), interpretation of microbial flow cytometric data (Davey and Davey
2011), embedding and decoding of digital watermarks (Usman et al. 2011), synthesis of
polymorphic combinational circuits (Gajda and Sekanina 2011), pipe break prediction
modeling (Xu et al. 2011), estimation of daily pan evaporation (Shiri and Kisi 2011),
software engineering predictive modeling (Afzal and Torkar 2011), modular neural
network programming (Tsai and Lin 2011), self-reproducing machines (Zykov et al.
2005), and steel beam load capacity prediction models (Gandomi et al. 2011).
Models evaluated using genetic programming are described by parse trees, as
shown in Figure 5.1. When randomly constructing a model, a node of the parse tree can
be chosen to be a function from the defined function set or a terminal from the defined
terminal set. When a function is chosen, two additional nodes in this case are generated to
be evaluated by that function. The selection of a terminal will terminate a branch of the
parse tree.
The parse tree structure has led to problems associated with genetic programming.
The problem of “bloat” refers to the expansion of parse trees to very large depths (Iba
2008, Koza 1992). Bloat is a result of over-fitting a data set. The bloat problem has been
addressed by defining the maximum depth that a tree can reach or by using a scoring
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function that penalizes larger solutions. Either solution to the bloat problem comes with a
cost. Using the maximum depth approach, a function that checks the depth of each newly
generated solution is called during each iteration of the algorithm, thus increasing the
computational cost of the process. When using a scoring function that penalizes larger
solutions, smaller programs that may not account for the complexity of the system tend to
dominate the population of models. Therefore, an optimal solution of moderate to large
depth that potentially better captures system complexity will have a smaller chance to be
evolved within the population of solutions.
Secondly, the parse tree structure leads to a highly discontinuous search space over
which the algorithm must find for the optimal model. Using the example equation
presented in Figure 5.1, the model as defined would asymptotically approach a steady
state after some period of time. If the “-” node was changed to a “+” node by a point
mutation, the model would no longer converge to a steady state. Instead, the model
would increase without bound, resulting in a poor fitness score and likely removal from
the population of solutions. The result is a convergence problem because the tree with the
“+” node is only 1 point mutation away from the optimal solution and therefore would be
desirable to keep in the population of solutions. As larger systems are explored, this
problem is exacerbated. Therefore, the phenotypic search space over which the algorithm
must explore is highly discontinuous as changing one node or terminal, analogous to
moving to a neighboring point in the search space, can yield a major change in the
behavior and therefore the score of the solution.
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Figure 5.1. Parse-tree solution structure for genetic programming. This one-equation system
is represented as a mass balance describing the change in some species x over time. Such an
equation could be generated using a genetic programming algorithm. Each node can be selected
to be one of a set of functions or one of a set of terminals, where each function requires two
arguments.

	
  
	
  

Gene expression programming (GEP) has been proposed to help address these

problems by encoding the different sizes and shapes of parse trees in linear solutions of
fixed length (Ferreira 2006). These linear solutions are then mapped to parse trees that
can be simulated. This approach mimics the genotype to phenotype mapping observed in
nature. In this study, the GEP enhancement to genetic programming was tailored to the
evolution of multi-variate systems describing reaction kinetic data to address the
discontinuous search space observed for these types of problems.
Genetic programming and GEP both use three primary evolutionary operations:
selection, recombination, and mutation. These operators are used to evoke changes in a
population of solutions thereby exploring a search space and converging on an optimal
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solution. Selection has received some attention as a function that can be tailored to
increase the efficiency and efficacy of a genetic programming algorithm (Gallagher and
Frean 2005, Gero and Kazakov 2001, Rowe et al. 2004, White and Srivastava 2011,
Whitley 1989). Varieties of selection operations that have been described include elite
selection (Bautista et al. 2013, Costa and Oliveira 2003), tournament selection (Blickle
and Lothar 1995), proportional selection (Schwefel 1993), and linear ranking selection
(Baker 1985). Elite selection requires the copying of an elite fraction of the best scoring
solution from one generation to the next. The rest of the next generation population of
solutions is made up of randomly recombined and mutated solutions. Tournament and
proportional selection bias the selection of solutions for recombination and mutation by
their score as determined by the scoring function. Linear ranking selection biases the
selection of solutions for recombination and mutation based upon a solutions rank within
the population as opposed to its score. Application of the appropriate selection operation
has the potential to increase efficiency and therefore feasibility of a GEP/genetic
programming approach.
It was hypothesized that by leveraging knowledge of reaction kinetic theory,
mechanistic mathematical models of complex biological interactions could be inferred
using an evolutionary algorithm. To test this hypothesis, an evolutionary algorithm that
optimized reaction kinetic models of biological systems from time series data sets was
developed. The traditional genetic programming methodology was enhanced to evolve
more complex reaction kinetic models describing multi-variate data sets using a GEPbased approach. The performance of this algorithm was evaluated by its ability to
recapitulate a generic viral dynamics model from a noisy in silico data set.
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5.2 System and Methods
In this proof-of-principle study, an evolutionary algorithm was used to rediscover
the mechanism described by a model of viral dynamics (Srivastava et al. 2002) using
computer-generated (in silico) data describing the system. The model, shown in
Equations 5.1 - 5.3, describes the rate of change of viral template (tem), viral genome
(gen), and viral structural proteins (struct) over time using six parameters. Figure 5.2
depicts a network diagram describing this system.

	
  

d[tem]
= k1[gen] − k2 [tem]
dt

(5.1)

d[gen]
= k3[tem] − k2 [gen] − k4 [gen][struct]
dt

(5.2)

d[struct]
= k5 [tem] − k6 [struct] − k4 [gen][struct]
dt

(5.3)
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Figure 5.2. General viral dynamics system (Srivastava et al. 2002). The published model of
general viral dynamics accounts for three species (tem, gen, and struct) participating in six
interactions described by six parameters (k1 è k6). Viral genome (gen) in the cytoplasm enters
the nucleus to become viral template (tem). Tem catalytically up-regulates production of gen as
well as structural proteins (struct). Both tem and struct can be degraded. Finally, struct can
encapsulate gen to form new viral progeny that leave the system.

In this model, k1 describes the rate by which gen enters the nucleus and becomes
tem. The model considers two degradation interactions, the degradation of tem at a rate of
k2 and the degradation of struct at a rate of k6. Tem catalytically up-regulates gen at a rate
of k3 and struct at a rate of k5. Finally, the interaction occurring at a rate of k4 models the
encapsulation of gen by struct to yield new viral progeny that leaves the system. Table
5.1 lists the parameter values for this model (Srivastava et al. 2002).
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Table	
  5.1.	
  Viral	
  Dynamics	
  Model	
  Parameters	
  
Parameter	
  
Value	
  
Units	
  
k1	
  
0.025	
  
day-‐1	
  
k2	
  
0.25	
  
day-‐1	
  
k3	
  
1.00	
  
day-‐1	
  
k4	
  
7.5*10-‐8	
  
molecules-‐1day-‐1	
  
k5	
  
1000	
  
day-‐1	
  
k6	
  
1.99	
  
day-‐1	
  

Genetic programming methods can represent programs or equations as trees made
up of functions and terminals. In assembling random trees, some potential models may
not include production or consumption terms for some of the mass balances. Potential
models also might not include explicit parameters for some interactions (equivalent to an
assumed reaction parameter of 1), and some terms may include tertiary and higher-order
interactions. For the evolution of reaction kinetic models, a heuristic limiting the search
space to models that include production and consumption terms for each species was
applied. Each production and consumption interaction in each candidate model was also
described by a reaction parameter. Finally, for the biological models of interest, it was
assumed that each interaction could include one or two reactants that could catalyze or be
consumed to generate one or two products (Levenspiel 1972). Tertiary and higher-order
interactions were therefore eliminated from consideration.
To tailor a genetic programming approach to generate desired reaction kinetic
models, the structure of candidate solutions was changed from a parse tree structure to
the structure shown in Figure 5.3A. This representation, inspired by a GEP approach,
encodes solutions as a “genotype,” such as a list or collection of lists, which are then
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mapped to a “phenotype,” such as a set of parse trees shown in Figure 5.3C. Therefore,
this evolutionary algorithm was programmed to map a list of reactants, reaction
parameters, products, and types of reactions to parse trees describing the time series
derivative of each variable under consideration. Such an approach resulted in a reduction
of the size of the search space over which the evolutionary algorithm navigated to find a
mechanistic mathematical model.
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Figure 5.3. Mapping of model genotype to model phenotype in evolutionary algorithm. (A)
Each potential model was encoded as an interaction table describing reactants, reaction
parameters, and products. Each interaction was also classified as a catalytic or consumption
interaction. This table, representing a list of reactions (B), was then translated using mass action
kinetic theory into a system of ordinary differential equations that could be represented as a set of
parse trees (C). These equations were then simulated and scored against an experimental data set
(D).

Another contributing factor to the large search space size the need to search for
both the optimal model structure and optimal model parameters. Even if a good model
structure was found, it was still unlikely that the algorithm would converge on the
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optimal set of parameters. To address this problem, parameter estimation was carried out
for every potential model against the experimental data during each generation of the
evolutionary algorithm.

5.3 Algorithm
It was observed in early versions of the algorithm that the absence of one
necessary interaction could result in a poor scoring model that might not survive in the
population of models (data not shown). This was yet another effect of the discontinuous
search space associated with these types of problems. Such behavior goes against the
assumption underlying evolutionary algorithms that optimal solutions could be built up
gradually from suboptimal solutions containing pieces of the optimal solution. To resolve
this issue, models were built up in a step-by-step fashion where only one equation was
allowed to be modified at a time.
The biochemical kinetics discovery algorithm is first described for an n-species
system. To generate a complete kinetic model, a mass balance for a single species was
evolved. Simultaneously, the mass balances for the other species were described by
fitted polynomials during scoring. Polynomials were fit to every three consecutive data
points and stored for use in the algorithm. This combination of one evolved mass balance
and n-1 polynomial fits was called an instance. One instance was generated for each
species such that every species had an instance in which it was represented by an evolved
mass balance equation. The general approach is outlined in Figure 5.4. The best scoring
mass balance from the collection of instances was taken as the most probable result and
that mass balance was fixed for the next step. The species described by this result was
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referred to as Species A. In other words, all of the remaining instances had their Species A
polynomial fit replaced by the Species A mass balance. During the next step, instances of
the evolutionary algorithm were carried out to evolve a mass balance for each of the
remaining species one at a time. The mass balance describing Species A was fixed, and
the mass balances describing the species not being evolved were described by a set of
polynomials. Again, the best scoring result from this set of instances was fixed for the
next step and this variable was defined as Species B. For a system of n-species, this
procedure would continue until only one species remained for which a mass balance had
not yet been evolved.
The evolutionary algorithm was then used to evolve a mass balance describing
this last species, while the mass balances describing the other species were fixed. This
species was defined as Species ξ where ξ related to the number of species for which a
time series data set existed. After this, the mass balance for Species A was re-evolved
using the evolutionary algorithm where mass balances describing Species B through ξ
were fixed. The existing result for Species A and the newly evolved solution were
compared by scoring with the current set of equations describing Species B through ξ and
the best scoring solution was kept and fixed for subsequent steps. The mass balances for
Species B through ξ were then re-evolved one at a time in the order that they were first
evolved. This method was carried out cyclically until the mass balances describing
Species A through ξ remained the same over one full cycle. The information gained from
these steps was ultimately used to seed the first generation population of a final
evolutionary step during which mass balances describing each of the species under
investigation were simultaneously evolved.
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Figure 5.4. Algorithm for the discovery of a biochemical kinetic model describing an nvariable system. Mass balances were evolved in a step-by-step manner to reduce the search
space during a single evolutionary algorithm instance. In the initial steps, species mass balances
were approximated by a set of polynomials fit to the corresponding data set until a mass balance
was evolved for that variable. Once a complete model was preliminarily proposed, each species’
mass balance was re-evolved one at a time until the system of mass balances had not changed
over one complete cycle. The model was finalized by carrying out one final evolutionary
algorithm optimization during which all mass balances were simultaneously evolved. Figure 5.5
summarizes the procedure used during each step to evolve an optimized mass balance.

Inputs for this evolutionary algorithm included the maximum number of
allowable interactions, the population size, the species under investigation, time series
data sets describing these species, the initial conditions used to collect the data set, any
fixed mass balances, and the number of generations to be run before the algorithm
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terminated. The number of interactions that potentially described a system increased
exponentially with the number of species under investigation. Therefore the number of
interactions allowed to describe a model was capped by the square of the number of
species (n2) plus one in order to maintain computational tractability. n2 represented the
number of interactions required for each species to be up-regulated by each other species,
to be consumed to produce each species, and to be degraded. Up to one additional
interaction was considered as binary interactions and constitutive production interactions
were also considered. Individual mass balances considered fewer interactions when
evolved and each species had the chance to participate in every interaction during the
simultaneous evolution step.
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Figure 5.5. Evolutionary algorithm for the discovery of biochemical mechanistic model. This
flowchart details the procedure for discovering a mechanistic model for an n-species system. An
initial population of candidate solutions was generated as encoded interaction tables. During each
generation of the algorithm, 10,000 random parameter combinations were generated and scored
using model calculations of species accumulation and estimates of experimental data derivatives.
The top five scoring parameter guesses were used as initial guesses to a numerical parameter
optimization function with the exception of single mass balance steps where parameters were not
numerically optimized until the final step. The best scoring parameter set was then used to score
the solution against the validation condition. An elite selection strategy was applied. The best
scoring solutions were copied to the next generation. Then solutions were selected, recombined,
and mutated to fill out and diversify the next generation’s population of solutions. This procedure
was repeated until the termination criterion was reached. The top scoring solution in the final
generation population was considered to be the optimized model.

Populations of potential solutions were generated and scored by simulating each
model using Mathematica on each training condition. Each potential solution in the first
generation population of individual mass balance runs was initialized with a constitutive
production term and a first order degradation term. The simulation results were compared
to the training data set and scored using the corrected Aikaike Information Criterion
(AICc) method (Aikaike 1974). Parameters were estimated for every solution every
generation. During the simultaneous optimization step, 10,000 random parameter sets
were generated and scores were estimated by comparing derivatives calculated using
model mass balances to derivatives calculated using the polynomial fits to the
experimental data set. The top five scoring parameter sets were then used as initial
guesses for Mathematica’s numerical optimization function. The objective function was
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minimization of the AICc score. Once optimized, each potential solution with the best
scoring parameter set was evaluated against a validation set of data using the AICc. This
score was associated with the potential solution during subsequent evolutionary
operations. During individual mass balance optimization steps, numerical integration was
not used to optimize parameters. Instead the best of the parameter sets, as determined by
AICc, was used for evaluation of the model on the validation data. The parameters for the
best scoring mass balances at the end of multiple trials of the evolutionary algorithm were
optimized using Mathematica and the best result was taken as the optimized solution.
Evolutionary algorithms utilize selection, recombination, and mutation operations
to generate diversity in a population of solutions and facilitate convergence towards an
optimized solution. An elite selection strategy was implemented where the top 20% of the
best scoring solutions in the population were copied unaltered to the next generation
population. The remaining 80% of the next generation population were made up of
solutions randomly selected two at a time from the previous generation population that
were given a chance to be recombined with each other and a chance to be mutated. In
order to address potential premature convergence brought on by decreasing diversity of
solutions in the population, the recombination rate, initiated at 90%, was decreased by
10% every x generations, where x is equal to 10% of the number of generations required
to terminate, until it reached 0%. Conversely, the mutation rate, initiated at 5%, was
increased by 5% every x generations until it reached 50%. In this way, solution mutation,
which introduces new alleles into a population thereby increasing diversity in the
population of solutions, was the favored evolutionary operation in later generations.
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This algorithm is computationally intensive, and its use may be limited by the
large amount of time it would take to run for systems of many species. To address this
issue, the operations that could be run in parallel, such as the simulation and scoring of
candidate solutions, and the execution of multiple instances of the algorithm, were
parallelized. The UCONN School of Engineering’s high performance computing cluster
consists of 768 Intel Xeon X5650 Westmere CPU cores over which parallel processes
can be allocated. Mathematica’s built-in parallel capabilities were used to carry out this
task.

5.4 Implementation
The biochemical kinetics discovery algorithm was implemented to evolve the
known mechanism of the generic viral dynamics system as a test case. An in silico data
set was generated as the input to the algorithm. Data was generated from the published
model using four conditions, listed in Table 5.2. Five independent samples were taken
every four simulated days over a period of two hundred days using 10% noise generated
over a normal distribution. During every step of the algorithm, a population of 30
potential solutions was evolved for up to 150 generations allowing for convergence of the
population. During each individual mass balance optimization step, twenty-four trials of
the evolutionary algorithm were carried out. The best scoring solution across all trials,
including the best result from the previous instance, was taken as the new optimized mass
balance. Likewise, eight trials of the evolutionary algorithm were carried out during the
final simultaneous optimization step where the best scoring result was taken as the
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optimized model. A maximum of four interactions were allowed to evolve during single
species steps and a cap of ten interactions was used for the combined evolution step.

Table	
  5.2.	
  Viral	
  Dynamics	
  Model	
  Conditions	
  For	
  Data	
  Generation	
  
Initial	
  
[tem]0	
  
[gen]0	
  
[struct]0	
  
Condition	
  
1	
  
1500	
  
0	
  
0	
  
2	
  
3000	
  
0	
  
0	
  
3	
  
5000	
  
0	
  
0	
  
	
  
4	
  
0
1500	
  
0	
  
During the first three steps of the algorithm, a mass action kinetic equation was
evolved first describing the change in [tem] over time, then the change in [gen] over time,
and finally the change in [struct] over time. The interactions described by these mass
balances are shown in Figure 5.6A. At this point in the evolution of the viral dynamics
model, only one true pathway had been identified (the degradation of struct).
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Figure 5.6. Evolution of the general viral dynamics model. (A) Carrying out the first three
steps of the algorithm (Figure 5.4) resulted in a complete model describing the three species
involved in the viral dynamics system. This proposed model consisted of eight interactions, one
of which was consistent with the published model. (B) After additional instances of single mass
balance optimization, the algorithm converged upon a model structure that was used to seed the
simultaneous optimization step. (C) After the step-by-step evolution of the model was complete,
the mass balances for all three species were simultaneously evolved. The result was two identical
scoring models, one of which evolved to the published general model of viral dynamics. Note:
Type “1” reactions are standard reactions, and type “0” reactions are catalytic reactions.
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The solution shown in Figure 5.6B was used to seed the population for the last
step during which all three mass balances were simultaneously re-evolved in order to
determine the optimized model. The final two interactions in the seed model, shown in
Figure 5.6B, describing the 0th-order production of tem and struct were eliminated to
allow for more new interactions to enter the population. These two interactions were
chosen for elimination because both tem and struct were up-regulated in other
interactions and the constitutive production of tem and struct described by this zero-order
reaction is very unlikely for this intracellular viral system. If these two interactions in fact
were part of the system’s network structure, they could have re-entered the model during
the simultaneous optimization step. After 70 generations of the simultaneous
optimization step, the algorithm converged on two solutions of equal score (AICc = 149.9). These solutions are shown in Figure 5.6C as Model 1 and Model 2. Model 1
correctly predicted the degradation of tem and struct, the consumption of gen to yield
tem, and the catalytic up-regulation of struct by tem. It incorrectly predicted that gen was
catalytically up-regulated by struct and that gen and struct associated to yield a net of one
struct molecule. Model 2 correctly predicted all six interactions of the generic viral
dynamics model with no additional interactions.
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Figure 5.7. Simulation of evolved viral dynamics models. (A) Simulation of Models 1 and 2
against in silico data sets generated for the three training conditions (columns 1-3) and the
validation condition (column 4) are shown. Both Models 1 and 2 had an AICc score of -149.9
when scored against the validation condition. (B) Models 1 and 2 were tested by comparing
simulation results to in silico data sets generated for four additional test conditions. Models 1 and
2 had nearly identical results on the first three test conditions (columns 1-3) but Model 2
significantly out-performed Model 1 on the fourth test condition (column 4).

The performance of Models’ 1 and 2 on the training conditions (columns 1-3) and
validation condition (column 4) are shown in Figure 5.7A. As expected by the identical
AICc score, both models were observed to accurately fit the in silico data set. To
differentiate between the two models, an in silico data set was generated by the same
procedure for four new conditions, listed in Table 5.3.

Table	
  5.3.	
  Viral	
  Dynamics	
  Model	
  Test	
  Conditions	
  
Initial	
  
[tem]0	
  
[gen]0	
  
Condition	
  
1	
  
10000	
  
0	
  
2	
  
0	
  
5000	
  
3	
  
500	
  
5000	
  
	
  
4	
  
0
0	
  

[struct]0	
  
0	
  
0	
  
1000	
  
1000	
  

Models 1 and 2 were simulated using each of the four new test cases, as shown in
Figure 5.7B, and scored against the in silico data sets. Both models yielded nearly
identical results on the first three test cases. However, models 1 and 2 showed
significantly different results when simulated against the fourth test case. Model 1 scored
poorly, based on its AICc value, as the struct molecules existing at t = 0 led to the up-
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regulation of gen and by extension tem. Model 2 had a better AICc score and accurately
predicted that the initial struct molecules would not up-regulate gen or tem and would be
degraded out of the system. Model 2 was therefore correctly selected as the optimized
mechanistic model for the general viral dynamics system. Table 5.4 compares the true
model to the evolved model and its parameters.

Table 5.4. Comparison of Known Equations to Generated Equations
Known Equations
Generated Equations
![!"#]
![!"#]
= 0.025 𝑔𝑒𝑛 − 0.25[𝑡𝑒𝑚]	
  	
  
= 0.025 𝑔𝑒𝑛 − 0.25[𝑡𝑒𝑚]	
  	
  
!"
!"
![!"#]

= 𝑡𝑒𝑚 − 0.025 𝑔𝑒𝑛 − 7.5 ∗
10!! [𝑔𝑒𝑛][𝑠𝑡𝑟𝑢𝑐𝑡]	
  	
  
![!"#$%"]
= 1000 𝑡𝑒𝑚 − 1.99[𝑠𝑡𝑟𝑢𝑐𝑡] −
!"
7.5 ∗ 10!! [𝑔𝑒𝑛][𝑠𝑡𝑟𝑢𝑐𝑡]	
  	
  
!"

![!"#]

= 0.99 𝑡𝑒𝑚 − 0.025 𝑔𝑒𝑛 −
7.46 ∗ 10!! [𝑔𝑒𝑛][𝑠𝑡𝑟𝑢𝑐𝑡]	
  	
  
![!"#$%"]
= 2570.4 𝑡𝑒𝑚 − 5.14[𝑠𝑡𝑟𝑢𝑐𝑡] −
!"
7.46 ∗ 10!! [𝑔𝑒𝑛][𝑠𝑡𝑟𝑢𝑐𝑡]	
  	
  
!"

5.5 Discussion
In this proof of principal study, an algorithm for determining the mechanistic
reaction kinetic network and associated kinetic parameters of a nonlinear system using
time series data was developed. The algorithm was validated by its ability to recapitulate
a generic nonlinear viral dynamics model. To overcome issues of intractability, reaction
kinetic theory was used to reduce the model search space by encoding models as
interactions with reactants, parameters, and products where reactions could be classified
as either describing consumption reactions or catalytic reactions. Convergence of the
algorithm was also facilitated by seeding biochemical species mass balances with a
production and consumption term as informed from domain specific knowledge. The
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algorithm did not require any prior knowledge of the relationship among measured
species.
Eight total instances of model evolution were required to generate a mechanistic
model of the viral dynamics system. The model went through two major intermediate
steps before arriving at two final models that fit the validation condition equally well.
Four scenarios using different initial conditions were used to differentiate between the
two models and one was selected as the optimized mechanistic model. The parameters
estimated with the evolved model were 160% of the parameters from the published
model used to generate the in silico data set, and in most cases were almost identical.
This means that the algorithm converged upon a sub-optimal parameter set for this
model.
Interactions between large numbers of species are commonly found in biological
systems; therefore it is important that a biochemical kinetics discovery algorithm be able
to analyze systems of many species. The enhancements to the traditional genetic
programming algorithm used in this study have the potential to carry out such an
analysis. The maximum number of interactions suggested is the square of the number of
species plus one, but it is possible to specify a reasonable number of interactions specific
to the system under investigation that goes beyond this value if deemed appropriate. It is
expected that running this algorithm for systems where a greater number of species are
being considered will take longer to converge on a mechanistic mathematical model.
Because of this, the published Mathematica code is designed to be monitored and
terminated when a potential solution has not improved during a sufficient number
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generations. The algorithm therefore has the potential to be beneficial in generation
models of complex biological systems.
Future research into the performance of this algorithm may identify ways to
improve its computational efficiency and by extension its ability to converge to an
optimal solution in a timely manner. One such approach may be to change the way by
which parameters for potential solutions are trained and validated. In this study, data
simulated using three different scenarios were used to infer solutions and a fourth was
used to validate solutions by assigning a score using AICc. This score was then used to
carry out evolutionary operations. Depending on the data set collected, it may be
necessary or preferable to assign a portion of a data to the training data set and another
portion to the validation data set, a common practice in the field of machine learning.
Similarly, when multiple candidate solutions emerge, as was the case in this study, there
is the potential to embed testing conditions into the algorithm. For example, a data set
describing the responses of the variables of interest to a perturbation could be recorded
and fed to the algorithm for this purpose. Also, another method of comparing the
candidate solutions, such as the F-test, could be utilized. These approaches would replace
the ad hoc testing done in this study.
Another such avenue for potential improvement will be regarding how
interactions are chosen to be involved in a potential solution. Depending on the likelihood
of an interaction being present in the system, a bias may be introduced that would make
particular interactions more or less likely to be present in a potential solution. For
example, a bias against dimerization interactions could be introduced when analyzing a
system such as the one in this study where such interactions are unlikely to occur. Such
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an improvement may prove critical in facilitating convergence of larger systems to an
optimized solution.
In conclusion, mechanistic models describing biological systems have the
potential to guide the discovery of drug targets and therapeutic strategies. This study
demonstrates a method of generating mechanistic mathematical models describing
biological systems from experimental data sets. This technology has the potential to be
useful in a variety of areas ranging from biomedical to biotechnological. For example,
for personalized medicine applications, the tailoring of mathematical models to an
individual’s disease state based upon their unique biochemical kinetic markers could
allow clinicians to make predictions about an individual’s disease state and optimize their
treatment. Biotechnologically, through the inference of bioprocesses, advances in the
discovery of pathways associated with microbial fuel production, for example, could lead
to novel insights into the optimization of these processes. Further, this algorithm has the
potential to be useful in any application where the relationship between biochemical
species is at question.
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CHAPTER 6
INFERENCE OF COHORT-SPECIFIC HIV-1 KINETICS
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6.1 Introduction
Human immunodeficiency virus type 1 (HIV-1) is an important disease that has
received significant interest from the modeling community (Aviran et al. 2010,
Bonhoeffer et al. 1997(a,b), Burg et al. 2009, Herz et al. 1996, Nowak and May 2000,
Perelson et al. 1996, Perelson 2002, Prosperi et al. 2009, Ribeiro and Bonhoeffer 2000,
von Kleist et al. 2010, Wu and Zhang 2010, Zeng and Yang 2010). In recent years, HIV1 treatments have significantly reduced AIDS-related mortalities and have enhanced
long-term disease control (Dybul et al. 2001, Fagard et al. 2003, Powderly 2002, Ruiz et
al. 2001). These benefits have been realized in large part via use of highly active
antiretroviral therapy (HAART) in clinical practice. The HAART strategy consists of
treating the disease with a combination of antiretroviral drugs. Despite advances in
efficacy over prior generation treatments, HAART is associated with risk of serious side
effects that include cardiovascular disease (Domingos et al. 2009), nephrotoxic effects
(Izzedine et al. 2009), and oral toxicities (Nittayananta et al. 2010). Up to 16% of
patients require modification or discontinuation of their HAART regimen due to drugrelated toxicities (Mocroft et al. 2005).
A major goal of developing mathematical models of diseases such as HIV-1 is to
understand the underlying pathology and to predict progression of the disease (Bogojeska
et al. 2010, Burg et al. 2009, Castiglione and Paci 2010, de Sousa and Cunha 2010,
Degon et al. 2008, Guedj and Neumann 2010, Hoffmann et al. 2002, Itakura et al. 2010,
Perelson et al. 1996, Smith and Ribeiro 2010, Srivastava et al. 2002, von Kleist et al.
2010, Wendelsdorf et al. 2010). One of the benefits arising from such a quantitative
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understanding is the potential to develop and optimize treatment strategies that maximize
health benefits while minimizing secondary toxicity effects.
Mathematical models of biochemical systems, such as HIV-1 pathogenesis, are
often defined by making assumptions as to the important reactions that consume and
produce the variables of interest. Reaction kinetic theory is then applied to formulate
mathematical models of these systems where reaction parameters are optimized using
experimental data sets. Therefore, many models of various sizes and structures have been
proposed for such systems taking into account a wide range of variables. Depending on
the variables taken into account and their predicted relationships, a system’s model
behavior can vary in response to perturbation.
A more robust approach to determine a mathematical model describing a
biochemical system, such as HIV-1 pathogenesis, would be to assume no prior
knowledge about the system and the way that the variables of interest interact. Therefore,
it would be useful to leverage an evolutionary algorithm (Blickle and Lothar 1995,
Chattopadhyay et al. 2013, Costa and Oliveira, Iba 2008, Koza 1992, Schmidt and Lispon
2009) to derive a reaction kinetic model describing the variables of interest, taking into
account all necessary variable interactions including some that may not be inherently
obvious. The resulting model could then be used to make predictions about the system as
well as to test and optimize potential therapeutics.
In this study, an evolutionary algorithmic approach was utilized to generate reaction
kinetic models from clinical data describing HIV-1 infection in three cohorts of HIV-1
positive subjects receiving three different HAART regimens. These cohort-specific
models allowed for the analysis of HIV-1 pathogenesis in each cohort as active
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biochemical pathways existing between CD4+ T-cells and HIV-1 were hypothesized. The
inferred pathways were used to evaluate HAART effectiveness in each cohort as well as
to makes predictions about the potential for viral rebound. Significantly, this study
demonstrates a method by which reaction kinetics models describing HIV-1 pathogenesis
can be inferred directly from clinical data.

6.2 Methods
6.2.1 Selection of Subject Data
CD4+ T-cell and HIV-1 data describing eight HIV-1 positive male subjects was
taken from Zhang et al. (Zhang et al. 1999). Subjects 1, 2, and 5 (Cohort 1) received 600
mg/day Zidovudine, 300 mg/day Lamivudine, and 1200 mg/day Ritonavir, subjects 3, 4,
and 6 (Cohort 2) received 600 mg/day Zidovudine, 300 mg/day Lamivudine, and 2400
mg/day Indinavir, and subjects 7 and 8 (Cohort 3) received 600 mg/day Zidovudine, 300
mg/day Lamivudine, 1200 mg/day Ritonavir, and 1200 mg/day Saquinavir. Since plasma
viremia was not detected after the 5th month of treatment, only data from time = 0 to
approximately the 5th month of treatment was considered for analysis. This data is
depicted in Figure 6.1.
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Figure 6.1. [CD4+] and [HIV-1] Data Describing HIV-1 Positive Subject Cohorts. CD4+ Tcell and HIV-1 concentration data from eight HIV-1 positive subjects was obtained from (Zhang
et al. 1999). Only the first five months of data were considered as this was the only period in
(Zhang et al. 1999) during which significant changes in [CD4+] and [HIV-1] were observed. The
subjects were re-organized into three cohorts, Cohort 1 (Subjects 1, 2, and 5), Cohort 2 (Subjects
3, 4, and 6), and Cohort 3 (Subjects 7 and 8), where the subjects making up each cohort each
received the same treatment regimen.

	
  
6.2.2

Optimization

of

Models

Using

an

Evolutionary

Algorithm

Reaction kinetic models of ordinary differential equations describing the change
in both [CD4+] and [HIV-1] over time were evolved using the algorithm depicted in
Figure 6.2. This algorithm is described in depth in Chapter 5. Data sets for Cohorts 1, 2,
and 3 were used as input to evaluations of the algorithm that resulted in a model specific
for that cohort. Model optimization steps (shown in blue and magenta in Figure 6.2) were
carried out using an evolutionary algorithm with evolutionary parameters defined as
follows; the population size was set to 30 models and a maximum of 150 iterations was
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Figure 6.2. An Evolutionary Algorithmic Approach for the Optimization of Cohort-Specific
HIV-1 Infection Models. Data sets describing cohorts of HIV-1 positive subjects were used as
the input to an evolutionary algorithmic approach designed to output a reaction kinetic model
describing a given cohort. First, mass balances were optimized using an evolutionary algorithm
for both CD4+ T-cells and HIV-1 individually. The best scoring mass balance, using AICc, was
fixed and the mass balance for the other variable, either CD4+ or HIV-1, was re-optimized. This
mass balance was then fixed and the mass-balance for the other variable was again optimized.
This cyclical behavior continued until both mass balances did not change over two steps. The
entire model consisting of both CD4+ and HIV-1 mass balances was simultaneously optimized
using an evolutionary algorithm with the result being the optimized reaction kinetic model.
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allowed. The recombination rate was reduced by 10% every 15 iterations, starting at 90%
and ending at 0%. Conversely, the mutation rate was increased by 5% every 15 iterations,
starting at 5% and ending at 50%.	
  
Candidate models were represented as a table of reactions, shown in Figure 6.3. A
reaction was defined by a set of reactants, a reaction parameter, and a set of products. The
set of reactants and products in each reaction was randomly chosen from the set {CD4+,
HIV-1, CD4+ + CD4+, HIV-1 + HIV-1, CD4+ + HIV-1, Null} and was randomly
designated as a catalytic reaction (parameter type = 0) where the reactants are not
consumed in the production of the product or as a reactant consuming reaction (parameter
type = 1). Single equation optimization steps were capped at four terms per equation and
up to five terms were allowed to make up the final model determined in the final
simultaneous optimization step.
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Figure 6.3. Representation of Potential Models in Evolutionary Algorithmic Approach.
During the generation of cohort-specific reaction kinetic models, evolutionary algorithms were
used to build up the final model in a step-by-step fashion. These evolutionary algorithms used a
population of potential models from which better scoring models emerged over several iterations.
Potential models were generated as tables of reactions, where each reaction was made up of
reactants, a reaction parameter (either describing a consumption or catalytic reaction), and
products. Using mass action kinetic theory, a table of reactions representing a potential model
was translated into a set of ordinary differential equations that could be simulated and scored
against a data set (not shown). The table of reactions from an optimized model was then
translated into a network diagram from which hypothesized reactions involving CD4+ T-cells and
HIV-1 could be visualized.

	
  
The reaction parameters describing each candidate model were optimized and
each model was assigned a score using the Akaike Information Criterion with correction
method (Aikaike 1974), where models that best fit the data received the lowest scores.
Using an elite selection strategy, the top 20% of a scored population of models was
copied unaltered to the next iteration’s population and the remaining 80% of that
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population was comprised of randomly selected solutions that were given a chance to
recombine and mutate to generate new and potentially better models. Eight instances of
each optimization step were run and the best-scoring model from among the final
populations of all eight instances was taken as the optimized solution.

6.2.3 Evolution of Cohort-Specific Models
During the first model optimization step of the algorithm, a mass balance was
optimized for both [CD4+] and [HIV-1] in separate runs where the mass balance for the
variable not under consideration was approximated by a polynomial fit to each series of
three data points. This approximation was necessary to numerically integrate the mass
balance of interest and to score it against the clinical data set. At the conclusion of this
step, the mass balance with the best score was fixed and the mass balance describing the
other variable was optimized again. During this step and in subsequent steps, the fixed
mass balance was used during the numerical integration of the model for scoring
purposes in lieu of the polynomial approximations.
The cycle of optimizing a single mass balance describing either [CD4+] or [HIV1] while the previously optimized mass balance describing the other variable was fixed
continued until there was no change in either the [CD4+] or [HIV-1] mass balance during
the previous two steps. The model represented by these two mass balances was then used
to seed the initial population of a final model optimization step where both mass balances
were evolved simultaneously. The result of this step was an optimized reaction kinetic
model describing reactions between CD4+ and HIV-1 specific to the cohort under
investigation.

	
  

105	
  

6.3 Results
Using the evolutionary algorithmic approach, reaction kinetic models describing
the change in CD4+ T-cell and HIV-1 concentration over time were evolved for three
cohorts of HIV-1 positive subjects. Data describing these cohorts was taken from Zhang
et al. (Zhang et al. 1999). Cohort 1 (three subjects) received 600 mg/day Zidovudine, 300
mg/day Lamivudine, and 1200 mg/day Ritonavir, Cohort 2 (three subjects) received 600
mg/day Zidovudine, 300 mg/day Lamivudine, and 2400 mg/day Indinavir, and Cohort 3
(two subjects) received 600 mg/day Zidovudine, 300 mg/day Lamivudine, 1200 mg/day
Ritonavir, and 1200 mg/day Saquinavir. CD4+ T-cell data included both uninfected and
HIV-1 infected cells.
Figure 6.4 shows the table of reactions and corresponding network diagrams
describing each cohort’s evolved model. Cohort 1’s kinetic model hypothesized that both
CD4+ T-cells and HIV-1 catalytically up-regulate production of HIV-1. Further, in one
pathway CD4+ T-cells and HIV-1 are consumed to yield CD4+ T-cells and in another
pathway they catalytically up-regulate CD4+ T-cell production. These pathways suggest
an active infection, as presumably HIV-1 infected CD4+ T-cells catalytically produce
new HIV-1, consistent with how HIV-1 is replicated. Similarly, the catalytic production
of HIV-1 by HIV-1 pathway represents infection of uninfected CD4+ T-cells, whose
concentration is approximately constant and factored into the reaction parameter, and
replication within these newly infected cells. Finally, the second order pathway
describing catalytic up-regulation of CD4+ T-cells by CD4+ T-cells and HIV-1 most
likely represents an infection pathway, as the concentration of HIV-1 is not being
reduced. Evidence of active treatment is shown in the second order pathway describing
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production of CD4+ T-cells by the consumption CD4+ T-cells and HIV-1. In this reaction,
HIV-1 enters the T-cell but due to the reverse transcriptase inhibitor cannot effectively
replicate or due to the protease inhibitor yield non-infectious HIV-1.

	
  
Figure 6.4. Evolved Cohort-Specific Reaction Kinetic Models. Reaction kinetic models
involving CD4+ T-cells and HIV-1 were evolved for Cohorts 1 (A), 2 (B), and 3 (C) using an
evolutionary algorithmic approach. In the evolutionary algorithmic approach, models were
represented as tables of reactions, where each reaction was made up of reactants, a reaction
parameter (either describing a consumption or catalytic reaction), and products. The table of
reactions was then used to generate a network diagram describing the mechanism hypothesized
by each model.

	
  
	
  

Cohort 2’s kinetic model hypothesized that CD4+ T-cells are constitutively

produced in one pathway and are eliminated in another pathway. In a third pathway,
CD4+ T-cells and HIV-1 are eliminated together. This system of reactions suggested that
treatment was effective. For example, constitutive production of CD4+ T-cells as well as
their elimination are pathways expected in a healthy subject. Further, the second order
interaction of CD4+ T-cells and HIV-1 elimination suggests that infected CD4+ T-cells
are detected and eliminated by the immune system.
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Cohort 3’s kinetic model hypothesized that CD4+ T-cells are eliminated in a
second order reaction. Also, CD4+ T-cells and HIV-1 are consumed to yield CD4+ Tcells. These pathways also suggest effective treatment as elimination of uninfected CD4+
T-cells is expected in healthy individuals and elimination of HIV-1 infected CD4+ T-cells
is beneficial in clearing the infection. Further, as seen in Cohort 1, production of CD4+ Tcells by the consumption CD4+ T-cells and HIV-1 suggests that HIV-1 entering the T-cell
does not effectively replicate due to the action of reverse transcriptase and protease
inhibitors.
	
  
Table 6.1. Cohort-Specific Model Reaction Parameters
Cohort 1
k1
k2

7.47*10

-6

7.35

Cohort 2
1/(H*t)
H/(C*t)

k3

158.06

1/t

k4

0.26

1/(C*t)

k1
k2
k3

*

69.22

Cohort 3
C/t

k1

0.018

1/(C*t)

-8

1/t

k2

0.045

1/(C*t)

-5

1/(H*t)

1.58*10

2.21*10 /
-2
3.36*10

3

C = cells/mm ; H = copies HIV-1/mL; t = months
* The reaction parameter was evolved to be 2.21*10-5 in the CD4+ mass balance and
3.36*10-2 in the HIV-1 mass balance.
	
  
	
  
	
  
	
  

The parameters evolved for each cohort’s reaction kinetic model are shown in

Table 6.1. Figure 6.5 shows the results of simulating these models with the evolved
parameters and plotting the results with each cohort’s data set. Models for Cohort 1 and
Cohort 2, AICc = 93.54 and AICc = 115.56 respectively, show good agreement with the
HIV-1 data set. HIV-1 concentration fell to undetectable limits in both Cohort 1 and
Cohort 2, consistent with the models, which hypothesized active treatment pathways.
Cohort 1’s model showed adequate agreement with the CD4+ T-cell data set but Cohort
2’s model did not show a strong correlation. CD4+ T-cell concentration is predicted to
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plateau in Cohort 1 where as in Cohort 2 the CD4+ T-cell concentration is predicted to
climb over the five-month time frame. This is most likely due to the active infection
pathways hypothesized for Cohort 1.

	
  
Figure 6.5. Cohort Model Simulations and Comparison To Clinical Data. Evolved models for
Cohort 1 (Subjects 1, 2, and 5), Cohort 2 (Subjects 3, 4, and 6), and Cohort 3 (Subjects 7 and 8)
were simulated and plotted with the clinical data set obtained from (Zhang et al. 1999). Models
for Cohorts 1 (AICc = 93.54), Cohort 2 (AICc = 115.56), and Cohort 3 (AICc = 130.80) showed
good agreement with the clinical HIV-1 data set. Cohort 1’s model showed adequate agreement
with the clinical CD4+ T-cell data but Cohort 2’s and 3’s model did not show a strong correlation.

	
  
	
  

Cohort 3’s model, AICc = 130.80, showed good agreement with HIV-1

concentration data but did not closely predict CD4+ T-cell concentration data due to the
lack of a CD4+ T-cell production pathway in the model. Even though a CD4+ T-cell
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production pathway should exist for this cohort, the evolved model determined the CD4+
T-cell and HIV-1 clearance pathways as most important and was therefore successful in
describing the down-regulation of HIV-1 in this cohort.

6.4 Discussion
This work significantly demonstrates a method by which interactions involving
CD4+ T-cells and HIV-1 can be inferred from HIV-1 positive subject cohort data. The
hypothesized interactions can be used to assess the effectiveness of a drug cocktail on a
cohort of subjects as well as to make predictions regarding viral rebound. In this study, an
evolutionary algorithmic approach was successfully able to hypothesize pathways for
three cohorts receiving different drug cocktails that showed the action of reverse
transcriptase and protease inhibitors in down-regulating HIV-1 infection. It was also
hypothesized that HIV-1 replication continued in Cohort 1. This result suggests that viral
rebound and potentially mutation may emerge if treatment was to be continued.
Interestingly, Zhang et al. found that viral replication did continue in Subject 5, a
member of Cohort 1, in the months after the period of early infection used for this study
(Zhang et al. 1999). Drug resistant HIV-1 strains were also found in this patient.
In addition to evolving reaction kinetic models for these three cohorts, models
were evolved for each individual subject using their specific [CD4+] and [HIV-1] data
(data not shown). Further, a reaction kinetic model was evolved to describe the cohort of
all eight subjects used in the Zhang et al. study by pooling their [CD4+] and [HIV-1] data
together (data not shown). It was found that models evolved for the individual subjects
did not describe mechanism that one would expect to exist between [CD4+] and [HIV-1]
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but rather merely provided a means by which the data could be fit. These results were due
to the limited amount of data available for each patient during the early infection period.
Likewise, the model evolved using data pooled from all eight subjects also did not
describe mechanism that one would expect to exist between [CD4+] and [HIV-1]. This
result was due to a loss in data resolution, as the subjects under investigation received
different treatment regimens. Therefore, the cohort models were selected for analysis.
It is anticipated that this evolutionary algorithmic method will be used to discover
biochemical mechanism in HIV-1 positive cohorts as well as in patient’s suffering from
other like diseases. The key to success of this method is the availability of relevant data;
large cohorts for whom large amounts of data exist will result in meaningful results.
Additionally, this method has the potential to be applied to data taken from a single
subject for which a large amount of dynamic data exists. The evolved model could then
be used to predict the disease course for this individual and to optimize a personal
treatment plan.
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CHAPTER 7
CONCLUSIONS AND FUTURE DIRECTIONS
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7.1 Conclusions
In conclusion, a GEP-based evolutionary algorithm was developed for the
evolution of mass action kinetic models describing systems of biochemical species from
time series data sets. These models are not built up assuming prior knowledge of how the
variables of interest interact but significantly infer the system’s reaction kinetics from the
data set. Therefore, this algorithm should be utilized as a hypothesis-generating tool
where pathways inferred using the evolutionary algorithm and previously not known to
be important in the system can be experimentally verified.
It was also shown that by applying the GEP-based evolutionary algorithm cohortspecific interactions between CD4+ T-cells and HIV-1 could be elucidated. These
interactions were used to determine the effectiveness of the HAART regimen prescribed
for each cohort and to make predictions about potential HIV-1 rebound. In a clinical
setting, the evolved models could be used to simulate the effectiveness of a HAART
regimen or to optimize a HAART regimen for that cohort as was done in Chapter 5.
It is anticipated that this methodology will be applied to reaction kinetic models
describing a variety of biochemical phenomena. Importantly, when applied to modeling
disease states, the GEP-based evolutionary algorithm has the potential to be applied to
evolve a model describing a subject’s unique set of biochemical markers. The model
could then be utilized to optimize a treatment strategy specific to that subject that would
most effectively treat the pathways associated with that individual’s disease state.
Application of the GEP-based evolutionary algorithm is not restricted to
biochemical problems but could also be useful in discovering patterns underlying any
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time series data set. Evolved models would become very useful as a first step in making
predictions about interactions between variables as well as in simulating the system.

7.2 Future Directions
This work opens up multiple avenues for future research. Currently, the GEPbased evolutionary algorithm assumes that all potential interactions have the same
probability of being part of the optimized reaction kinetic model. In some systems of
interest, for example in the evolution of the general viral dynamics model or in the
evolution of the HIV dynamics model, it is known that some interactions, such as
dimerization of biochemical species, are not likely to occur. Therefore, the GEP-based
evolutionary algorithm could be altered to include biases that would result in an increased
probability that a sub-population of interactions enter a candidate model and a lower
probability that another sub-population of less likely interactions are chosen to be part of
a candidate model.
Further, candidate models in the GEP-based evolutionary algorithmic approach
were trained (the model’s parameters were optimized) on a portion of the data set and
then scored by validating each model with its optimized parameters on another portion of
the data set. In the general viral dynamics study, see Chapter 5, where data was available
from multiple experiments across multiple initial conditions, data from three of the four
initial conditions was used as the model training data set and data from the fourth initial
condition was used as the model validation data set. The training and validation of
solutions in this algorithm is an area that deserves further scrutiny as more optimal ways
of dividing an experimental data into training and validation data sets may yield better
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convergence on optimal solutions has the potential to greatly decrease the computational
intensity involved in executing this algorithm.
Finally, most of the GEP-based evolutionary algorithm’s evaluation time is spent
on optimizing sets of parameters for candidate models. This step is crucial in reducing the
solution space, as sub-optimal parameter sets are not considered. Currently,
Mathematica’s NMinimize function is used to carry out parameter optimization.
Implementation of more efficient and computationally less intense methods to carry out
parameter optimization may result in increased performance of the algorithm and the
potential for the algorithm to be applied to systems with a large number of variables.
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CHAPTER 9
APPENDIX
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9.1 Appendix 1: Elite Variant Selection Strategy Code
The following code was written in Common Lisp.
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9.2 Appendix 2: In silico HIV-1 Positive Subject Population Analysis Code
The following code was written in Common Lisp.
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9.3 Appendix 3: Biochemical Kinetics Inference Algorithm Code
9.3.1 Instructions
The code contained in this package is intended to be used for the generation of
mass action kinetic models from time series biological data sets. The four programs
included in the MathematicaCode folder are as follows:
1) EvolutaionaryAlgorithm_SingleVariableStep
2) EvolutaionaryAlgorithm_SingleVariableStepComparisonOfMultipleInstances
3) EvolutaionaryAlgorithm_SingleVariableStepComparisonOfMultipleInstancesWorkAround
4) EvolutaionaryAlgorithm_CompleteModelOptimization(FinalStep)
The programs are intended to be used iteratively. First, the
EvolutaionaryAlgorithm_SingleVariableStep program is to be used to evolve mass
balances describing each variable of interest separately. This means that for a 3-variable
system you would use 3 different versions of this code (changing it for each variable by
following the directions included with the program). It is recommended that multiple
instances if each program be run to validate results.
When multiple instances are run, the
EvolutaionaryAlgorithm_SingleVariableStepComparisonOfMultipleInstances program is
used to identify the result that should be used to describe a variable's mass balance going
forward. THE VARIABLE FOR WHICH A MASS BALANCE IS BEING EVOLVED
MUST BE DEFINED AT THE HEAD OF EACH VARIABLE LIST AND BE
CONSIDERED TO BE VARIABLE 1 WHEN LISTING DATA. A numerical parameter
optimization function is included in this program; if the program fails to terminate in a
reasonable amount of time the parameter optimization package may be failing to
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converge. In this case, the
EvolutaionaryAlgorithm_SingleVariableStepComparisonOfMultipleInstancesWorkArou
nd program can be used to leverage the output from the
EvolutaionaryAlgorithm_SingleVariableStepComparisonOfMultipleInstances program to
find the best result.
Once all mass balances have been found, fix the mass balance for the variable that
resulted in the best (lowest) score and re-run the
EvolutaionaryAlgorithm_SingleVariableStep program for the remaining variables while
also defining the mass balance for the fixed variable within the code. Again, for multiple
instances use
EvolutaionaryAlgorithm_SingleVariableStepComparisonOfMultipleInstances/Evolutaion
aryAlgorithm_SingleVariableStepComparisonOfMultipleInstancesWorkAround
programs to identify the best solution.
After mass balances have been fixed for all but one variable, run
EvolutaionaryAlgorithm_SingleVariableStep/EvolutaionaryAlgorithm_SingleVariableSte
pComparisonOfMultipleInstances programs to find a solution. Begin the iteratively reevolve variable mass balances in this manner beginning with the variable for which a
mass balance was defined first. Iterate until the mass balances for each variable have not
changed over one complete cycle.
Mass balances should now be proposed for each variable under investigation. Use
the EvolutaionaryAlgorithm_CompleteModelOptimization(FinalStep) to carry out one
final simultaneous evolution step. The result of this program will be a mass action kinetic
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model. Again, it is suggested that multiple instances of this program be run. The result
with the best (lowest) score will be the optimized mass action kinetic model.

The following code was written in Mathematica.

	
  

139	
  

9.3.2 EvolutionaryAlgorithm_SingleVariableStep.nb
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9.3.3 EvolutionaryAlgorithm_SingleVariableStepComparisonOfMultipleInstances.nb
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9.3.4 EvolutionaryAlgorithm_SingleVariableStepComparisonOfMultipleInstancesWorkAround.nb
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9.3.5 EvolutionaryAlgorithm_CompleteModelOptimization(FinalStep).nb
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